ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -16 مورد

Clozapine: Drug information

Clozapine: Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Clozapine: Patient drug information" and "Clozapine: Pediatric drug information"

For abbreviations, symbols, and age group definitions show table
ALERT: US Boxed Warning
Severe neutropenia:

Clozapine treatment has caused severe neutropenia, defined as an absolute neutrophil count (ANC) less than 500/mm3. Severe neutropenia can lead to serious infection and death. Prior to initiating treatment, a baseline ANC must be at least 1,500/mm3 for the general population and must be at least 1,000/mm3 for patients with documented Duffy-null associated neutrophil count (formerly called benign ethnic neutropenia). During treatment, patients must have regular ANC monitoring. Advise patients to immediately report symptoms consistent with severe neutropenia or infection (eg, fever, weakness, lethargy, sore throat).

Because of the risk of severe neutropenia, clozapine is available only through a restricted program under a Risk Evaluation Mitigation Strategy (REMS) called the Clozapine REMS Program. Note: As of February 24, 2025, the FDA does not expect prescribers, pharmacies, and patients to participate in the Clozapine REMS Program or to report ANC results before pharmacies dispense clozapine. The FDA still recommends that prescribers monitor patients’ ANC according to the monitoring frequencies described in the prescribing information. The FDA will work with the clozapine manufacturers to update the prescribing information and eliminate the Clozapine REMS. Refer to the following for additional information https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-clozapine.

Orthostatic hypotension, bradycardia, syncope:

Orthostatic hypotension, bradycardia, syncope, and cardiac arrest have occurred with treatment. The risk is highest during the initial titration period, particularly with rapid dose escalation. These reactions can occur with the first dose, with dosages as low as 12.5 mg/day, or when restarting patients who have had even a brief interruption in treatment. Initiate treatment at 12.5 mg once or twice daily, titrate slowly, and use divided dosages to minimize risk. Use cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (eg, dehydration, use of antihypertensive medications).

Seizures:

Seizures have occurred with treatment. The risk is dose-related. Initiate treatment at 12.5 mg, titrate gradually, and use divided dosing. Use caution when administering to patients with a history of seizures or other predisposing risk factors for seizure (CNS pathology, medications that lower the seizure threshold, alcohol abuse). Caution patients about engaging in any activity where sudden loss of consciousness could cause serious risk to themselves or others.

Myocarditis, pericarditis, cardiomyopathy and mitral valve incompetence:

Fatal myocarditis and cardiomyopathy have occurred with treatment. Discontinue clozapine and obtain a cardiac evaluation upon suspicion of these reactions. Generally, patients with clozapine-related myocarditis or cardiomyopathy should not be rechallenged with clozapine. Consider the possibility of myocarditis, pericarditis, or cardiomyopathy if chest pain, tachycardia, palpitations, dyspnea, fever, flu-like symptoms, hypotension, or electrocardiogram (ECG) changes occur.

Increased mortality in elderly patients with dementia-related psychosis:

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Clozapine is not approved for use in patients with dementia-related psychosis.

Brand Names: US
  • Clozaril;
  • Versacloz
Brand Names: Canada
  • AA-Clozapine;
  • Clozaril;
  • GEN-Clozapine
Pharmacologic Category
  • Second Generation (Atypical) Antipsychotic
Dosing: Adult

Dosage guidance:

Safety:

Due to risk of severe neutropenia, obtain an ANC prior to initiation. Baseline ANC must be ≥1,500/mm3 for the general population and ≥1,000/mm3 for patients with documented Duffy-null associated neutrophil count (formerly called benign ethnic neutropenia). Continue regular monitoring of ANC based on prescribing information.

Antipsychotics are not indicated for use in patients with catatonia and may worsen psychosis and increase risk for neuroleptic malignant syndrome in this setting (Ref).

Clinical considerations : Consult a psychiatry specialist for all management decisions; select antipsychotic carefully based on patient preference, clinical characteristics, history, comorbidities, and medication adverse effects profile (Ref). May administer with prophylactic stool softener or laxative to decrease risk of constipation (Ref).

Agitation/Aggression and psychosis associated with dementia, severe or refractory

Agitation/Aggression and psychosis associated with dementia, severe or refractory (alternative agent) (off-label use):

Note: For short-term use while addressing underlying causes of severe symptoms. Patients with dementia with Lewy bodies are at increased risk for severe adverse reactions; caution is required even with low doses (Ref).

Oral: Initial: 6.5 to 12.5 mg at bedtime; increase by 12.5 mg every 3 to 5 days as needed based on response and tolerability (given as divided doses in the morning and at bedtime); mean doses of 60 mg/day have been studied (Ref). In patients without a clinically significant response after 4 weeks, taper and withdraw therapy. In patients with an adequate response, attempt to taper and withdraw therapy within 4 months, unless symptoms recurred with a previous taper attempt. Assess symptoms at least monthly during taper and for at least 4 months after withdrawal of therapy (Ref).

Bipolar disorder, treatment resistant

Bipolar disorder, treatment resistant (off-label use):

Acute mania (monotherapy or adjunctive therapy): Oral: Initial: 25 mg daily; increase daily dose based on response and tolerability in 25 mg increments at intervals ≥1 day to a maximum dose of 550 mg/day in 1 to 3 divided doses. Usual daily dose ~100 to 300 mg/day in 1 to 3 divided doses (Ref).

Maintenance treatment (monotherapy or adjunctive therapy): Continue dose and combination regimen that was used to achieve control of the acute episode (Ref).

Psychosis in Parkinson disease

Psychosis in Parkinson disease (off-label use): Oral: Initial: 6.25 mg/day, in 1 or 2 divided doses; increase daily dose based on response and tolerability in 6.25 or 12.5 mg increments at intervals of 3 to 7 days to a maximum dose of 50 mg/day (Ref).

Schizophrenia, treatment resistant and Suicidality in schizophrenia or schizoaffective disorder

Schizophrenia, treatment resistant and Suicidality in schizophrenia or schizoaffective disorder:

Note: Due to its adverse effect profile, use is generally reserved for resistance to ≥2 other antipsychotics or schizophrenia or schizoaffective disorder with persistent suicidality (Ref); may also use in patients with a history of parkinsonism or tardive dyskinesia during treatment with other antipsychotics (Ref).

Initial: Oral: 12.5 mg once or twice daily, followed by titration.

Titration: Oral: Increase daily dose in increments of 25 to 50 mg at intervals ≥1 day to a target dose of 300 mg/day in 1 to 2 divided doses by the end of 2 weeks; monitor for anticholinergic effects, orthostatic hypotension, sedation and seizure risk during titration. Some experts increase by 25 to 50 mg twice weekly, reaching 300 mg/day by weeks 3 to 6, depending upon urgency and tolerability (Ref). Once at target dose, may further adjust in increments not exceeding 50 mg and no more frequently than twice weekly based on response, tolerability, and serum concentrations. Usual effective dose: 300 to 600 mg/day; maximum total daily dose: 900 mg/day. Once stabilized on an effective dose, all or most of the dose can be given once daily at bedtime (Ref).

Note: In patients with cardiac disease or at risk for orthostatic hypotension, more gradual titration and a lower target dose may be necessary (Ref).

Dose adjustment in smokers: Dose requirements may be higher in patients who smoke. If a patient stops smoking during therapy, consider empirically reducing the daily dose to 60% to 70% of the current dose (Ref).

Reinitiation of therapy:

If 1 day of clozapine is missed: Resume clozapine treatment at 40% to 50% of the previous total daily dose; if dose is well tolerated, may increase more rapidly than with initial titration.

If 2 days of clozapine are missed: Resume clozapine treatment at ~25% of the previous total daily dose; if dose is well tolerated, may increase more rapidly than with initial titration.

If dosing is interrupted for more than 2 days, reinitiate therapy at 12.5 mg once or twice daily; if dose is well tolerated, may increase more rapidly than with initial titration.

Discontinuation of therapy: In the treatment of chronic psychiatric disease, switching therapy rather than discontinuation is generally advised if side effects are intolerable or treatment is not effective. If patient insists on stopping treatment, in general, gradual dose reduction (ie, over several weeks to months) is advised to detect a re-emergence of symptoms and to avoid withdrawal reactions (eg, agitation, alternating feelings of warmth and chill, anxiety, diaphoresis, dyskinesias, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, vertigo) unless discontinuation is due to significant adverse effects; the manufacturer recommends reducing the clozapine dose gradually over a period of 1 to 2 weeks if termination of therapy is not related to neutropenia. Monitor closely to allow for detection of prodromal symptoms of disease recurrence (Ref).

Switching antipsychotics: An optimal universal strategy for switching antipsychotic drugs has not been established. Strategies include: cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic) and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). In patients with schizophrenia at high risk of relapse, the current medication may be maintained at full dose as the new medication is increased (ie, overlap); once the new medication is at therapeutic dose, the first medication is gradually decreased and discontinued over 1 to 2 weeks (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function:

Note: There is no pharmacokinetic data available in kidney impairment. The following recommendations are based on the low urinary excretion of unchanged clozapine in healthy volunteers, and a physiologically based pharmacokinetic model, which reported AUCs increased by 50% to 70% in patients with eGFR <60 mL/minute/1.73 m2 (Ref).

eGFR ≥60 mL/minute/1.73 m2: Oral: No dosage adjustment necessary (Ref).

eGFR <60 mL/minute/1.73 m2: Oral: Start with doses on the lower end of the usual indication-specific recommended range. Utilize a slower titration than that recommended in patients with normal kidney function and monitor closely for tolerability and response (Ref).

Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m2): Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Younger patients (<55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (Ref).

Oral: No data: No dosage adjustment necessary (Ref).

Hemodialysis, intermittent (thrice weekly): Unlikely to be significantly dialyzable (highly protein bound, large Vd): Oral: Dose as for patients with eGFR <60 mL/minute/1.73 m2 (Ref).

Peritoneal dialysis: Unlikely to be significantly dialyzable (highly protein bound, large Vd): Oral: Dose as for patients with eGFR <60 mL/minute/1.73 m2 (Ref).

CRRT: Unlikely to be significantly dialyzable (highly protein bound, large Vd): Oral: Dose as for patients with eGFR <60 mL/minute/1.73 m2 (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): Unlikely to be significantly dialyzable (highly protein bound, large Vd): Oral: Dose as for patients with eGFR <60 mL/minute/1.73 m2 (Ref).

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; however, labeling suggests that dose reductions may be necessary with significant impairment.

Dosing: Older Adult

Note: Clinical considerations: Avoid for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. If used, consider deprescribing attempts to assess continued need and/or lowest effective dose. Of note, use in certain indications may be appropriate (eg, schizophrenia, bipolar disorder) (Ref). Consult a psychiatry specialist for all management decisions (Ref).

Indication-specific dosing:

Schizophrenia , treatment resistant and Suicidality in schizophrenia or schizoaffective disorder:

Oral: Refer to adult dosing for full details. Experience in older adults is limited. Initial: 12.5 mg once daily for 3 days, then increase to 25 mg once daily for 3 days as tolerated. May increase daily dose, based on response and tolerability, in increments of 12.5 to 25 mg every 3 days, up to 700 mg/day in 1 to 2 divided doses (mean dose: 300 mg/day) (Ref).

All other indications: Refer to adult dosing; dosages in the lower range of recommended adult dosing are generally sufficient. Titrate dosage slowly and monitor carefully.

Dosing: Pediatric

(For additional information see "Clozapine: Pediatric drug information")

Dosage guidance:

Safety: Due to risk of severe neutropenia, obtain a baseline ANC. In order to initiate treatment, minimum baseline ANC values must be met; for the general population, the ANC must be ≥1,500/mm3 and for patients with documented Duffy-null associated neutrophil count (benign ethnic neutropenia), the ANC must be ≥1,000/mm3. Laboratory hematology results may be presented in different units; 1 mcL = 1 mm3. Continue regular monitoring of ANC based on prescribing information.

Clinical considerations: Due to risks for GI hypomotility, consider concomitant use of preventative treatments (eg, high fiber diet, exercise, fluids, laxatives) for constipation (Ref). Titration to the lowest effective dose should be used to minimize potential adverse effects (see "Adverse Reactions [Significant]: Considerations") including seizures (clozapine may decrease seizure threshold) (Ref).

Schizophrenia; treatment resistant

Schizophrenia; treatment resistant: Limited data available:

Note: Childhood onset schizophrenia (COS) (ie, diagnosed before 13 years of age) is very rare and often misdiagnosed, thus limiting sample sizes for study (eg, approximately 30% to 50% of patients with affective or other atypical psychotic symptoms are misdiagnosed as COS, and over 90% of the initial referrals to the NIMH study of COS received alternate diagnoses (Ref)). Meta-analysis and systematic review showed clozapine is safe, effective, and superior to other antipsychotics in treatment of childhood and adolescent onset schizophrenia (Ref). Dose should be individualized based on tolerability, concomitant antipsychotic therapy, and clinical response.

Initial dose:

Children ≥6 years: Oral: 6.25 or 12.5 mg once daily.

Adolescents: Oral: 12.5 mg once or twice daily.

Titration and maintenance dosing: Increase daily dose by ≤25 mg increments (lower initial doses should use smaller increments [1 to 2 times the starting dose]), as tolerated, every 3 to 5 days, to a target dose of 200 to 400 mg/day in divided doses. Dose may be divided, with a higher dose at bedtime; if excessive daytime sedation, entire dose may be at bedtime (Ref). Mean effective dose range in most pediatric studies: 220 to 431 mg/day (Ref).

Reinitiation of therapy: Based on experience in adult patients, if dosing is interrupted for ≥48 hours, therapy must be reinitiated at initial doses to minimize the risk of hypotension, bradycardia, and syncope; if dose is well tolerated, may be increased more rapidly than with initial titration, unless cardiopulmonary arrest occurred during initial titration, then retitrate with extreme caution.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Discontinuation of therapy: Children and Adolescents: In adults, the manufacturer recommends reducing the dose gradually over a period of 1 to 2 weeks if termination of therapy is not related to neutropenia. The American Academy of Child and Adolescent Psychiatry (AACAP), American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), National Institute for Health and Care Excellence (NICE), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid withdrawal symptoms and minimize the risk of relapse (Ref); risk for withdrawal symptoms may be highest with highly anticholinergic or dopaminergic antipsychotics (Ref). When stopping antipsychotic therapy in patients with schizophrenia, the CPA guidelines recommend a gradual taper over 6 to 24 months and the APA guidelines recommend reducing the dose by 10% each month (Ref). Continuing antiparkinsonism agents for a brief period after discontinuation may prevent withdrawal symptoms (Ref). When switching antipsychotics, three strategies have been suggested: Cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic), overlap and taper (maintaining the dose of the first antipsychotic while gradually increasing the new antipsychotic, then tapering the first antipsychotic), and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). Evidence supporting ideal switch strategies and taper rates is limited and results are conflicting (Ref).

Dosing: Kidney Impairment: Pediatric

All patients: There are no dosage adjustments provided in the manufacturer's labeling; however, labeling suggests that dose reductions may be necessary with significant impairment but does not provide specific dosing recommendations.

Dosing: Liver Impairment: Pediatric

All patients: There are no dosage adjustments provided in the manufacturer's labeling; however, labeling suggests that dose reductions may be necessary with significant impairment.

Adverse Reactions (Significant): Considerations
Anticholinergic effects

Anticholinergic activity of clozapine at usual therapeutic doses is considered to be high, relative to other second-generation antipsychotics and may lead to nonadherence (Ref). Peripheral anticholinergic effects include blurred vision, xerostomia, urinary retention, tachycardia, and constipation (potentially resulting in severe and potentially fatal complications such as intestinal obstruction and ileus). Central anticholinergic effects may result in cognitive dysfunction, including confusion, new-onset delirium, and an increased risk of falling, particularly in older adults. However, there are conflicting data on the cognitive effects of clozapine with some studies showing a beneficial effect (Ref).

Mechanism: Dose-related; believed to be mediated primarily through antagonism at muscarinic receptors (Ref). In addition, some anticholinergic effects are also potentiated by other pathways, such as clozapine's antiadrenergic effects contributing to urinary retention potential and clozapine’s antagonism of serotonin receptors in GI smooth muscle contributing to constipation potential (Ref). Cognitive effects may also be further mediated by clozapine-induced D2 blockade and by differences in plasma concentration ratios of clozapine and its major metabolite, N-desmethylclozapine (NDMC), with some evidence suggesting that NDMC may be associated with cognitive improvement (Ref).

Risk factors:

Variable and dependent upon:

• Total cumulative anticholinergic burden (Ref)

• Baseline cognitive function (Ref)

• Comorbidities (Ref)

• Older adults (Ref)

• Interindividual variability of the pharmacokinetic and pharmacodynamic parameters (Ref)

Dyslipidemia

Clozapine is strongly associated with dyslipidemia, which is a component of the metabolic syndrome observed with this pharmacologic class. Dyslipidemia observed with clozapine primarily manifests as hypercholesterolemia and/or hypertriglyceridemia (Ref). A 10-year naturalistic study of clozapine-treated adult patients suggested an increased risk of mortality from cardiovascular disease (CVD) secondary to disorders such as obesity, diabetes, hypertension, and hyperlipidemia; however, patients with schizophrenia have a higher risk of CVD than the general population due to lifestyle habits (eg, smoking, physical inactivity, unhealthy diet), regardless of medication use (Ref).

Mechanism: The mechanism is not entirely understood and is likely multifactorial (Ref).

Onset: Varied; metabolic alterations from antipsychotics can develop in as short as 3 months after initiation (Ref).

Risk factors:

• Family history of hyperlipidemia (Ref)

• Schizophrenia (regardless of medication use) is associated with a higher rate of morbidity/mortality compared to the general population primarily due to CVD (Ref)

• Higher doses (potential risk factor). Note: Conflicting data exist on a correlation between clozapine levels and triglycerides or cholesterol; however, higher clozapine levels have been associated with an increased risk for metabolic syndrome in general (clozapine levels 1.5 times higher in patients with metabolic syndrome compared to those without) (Ref)

• Specific antipsychotic: Risk of dyslipidemia and overall metabolic disturbances appears to be high with clozapine (Ref)

Extrapyramidal symptoms

Clozapine may cause extrapyramidal symptoms (EPS), also known as drug-induced movement disorders, but EPS is typically rare or uncommon in adults treated with therapeutic doses of clozapine compared to first-generation (conventional) antipsychotics, and in some studies, has been equal to or less than the control group. Incidence may be higher in children and adolescents, particularly with akathisia (Ref); however, some limited evidence is conflicting (Ref). Antipsychotics can cause four main extrapyramidal reactions: Acute dystonia, drug-induced parkinsonism, akathisia, and tardive dyskinesia. Of these, clozapine is very rarely associated with acute dystonia or dyskinesia (acute or tardive) and some clinicians use a switch to clozapine to mitigate tardive dyskinesia induced by other antipsychotics (Ref). EPS presenting as dysphagia, esophageal dysmotility, or pulmonary aspiration have also been reported with antipsychotics which may not be recognized as EPS. Clozapine has been the sole antipsychotic in several of these case reports, although it is unknown the role and to what degree clozapine-induced EPS, -sialorrhea, and/or -anticholinergic properties may have contributed (Ref).

Mechanism: EPS: Dose-related; due to antagonism of dopaminergic D2 receptors in nigrostriatal pathways; however, compared to other antipsychotics, clozapine has a much lower affinity for D2 receptors and displays rapid dissociation from D2 receptors (‘fast off’ phenomenon), which may contribute to the lower propensity of clozapine for EPS development (Ref).

Onset:

Antipsychotics in general:

Acute dystonia: Rapid; in the majority of cases, dystonia usually occurs within the first 5 days after initiating antipsychotic therapy (even with the first dose, particularly in patients receiving parenteral antipsychotics) or a dosage increase (Ref).

Drug-induced parkinsonism: Varied; onset may be delayed from days to weeks, with 50% to 75% of cases occurring within 1 month and 90% within 3 months of antipsychotic initiation, a dosage increase, or a change in the medication regimen (such as adding another antipsychotic agent or discontinuing an anticholinergic medication) (Ref).

Akathisia: Varied; may begin within several days after antipsychotic initiation but usually increases with treatment duration, occurring within 1 month in up to 50% of cases, and within 3 months in 90% of cases (Ref).

Tardive dyskinesia: Delayed; symptoms usually appear after 1 to 2 years of continuous exposure to a dopamine 2 receptor antagonist and almost never before 3 months, with an insidious onset, evolving into a full syndrome over days and weeks, followed by symptom stabilization, and then a chronic waxing and waning of symptoms (Ref).

Esophageal dysfunction (associated with extrapyramidal symptoms): Varied; ranges from weeks to months following initiation (Ref).

Risk factors:

EPS (in general):

• Prior history of EPS (Ref)

• Higher doses (Ref)

• Younger age (in general, children and adolescents are usually at higher risk for EPS compared to adults) (Ref); however, some limited evidence for clozapine is conflicting (Ref)

• Specific antipsychotic: Clozapine has a very low propensity to cause EPS in adults (Ref)

Acute dystonia:

• Males (Ref)

• Young age (Ref)

Drug-induced parkinsonism:

• Females (Ref)

• Older patients (Ref)

Akathisia:

• Higher antipsychotic dosages (Ref)

• Polypharmacy (Ref)

• Mood disorders (Ref)

• Females (Ref)

• Older patients (Ref)

Tardive dyskinesia: Note: It is unlikely that clozapine causes tardive dyskinesia (Ref)

• Age >55 years (Ref)

• Cognitive impairment (Ref)

• Concomitant treatment with anticholinergic medications (Ref)

• Diabetes (Ref)

• Diagnosis of schizophrenia or affective disorders (Ref)

• Females (Ref)

• Greater total antipsychotic exposure (especially first-generation antipsychotics) (Ref)

• History of extrapyramidal symptoms (Ref)

• Substance misuse or dependence (Ref)

• Race (White or African descent). Note: Although early literature supported race as a potential risk factor for tardive dyskinesia (Ref), newer studies have challenged this assertion (Ref)

Esophageal dysfunction:

• Older adults (Ref)

Fever

Drug-induced fever is common with clozapine following initiation. It is usually benign, transient, and self-limiting (lasting an average of 2.5 days and resolving by day 16 even if therapy is continued). However, fever warrants further investigation to rule out other nonbenign potential causes (eg, neuroleptic malignant syndrome [NMS], severe neutropenia, infection, myocarditis, clozapine-induced hypothermia) (Ref).

Mechanism: Unknown; various underlying mechanisms have been proposed (eg, infection, mild form of NMS, allergic reaction), but recent evidence suggests that clozapine-induced fever is due to a generalized inflammatory response to the immunomodulating effects of clozapine on the cytokine system, particularly due to increased levels of interleukin-6 and C-reactive protein (Ref).

Onset: Intermediate; usually occurs in the first 3 to 4 weeks of treatment (Ref).

Risk factors:

• Titration-related (potential risk factor with dose increases >50 mg/week) (Ref). Note: Fever does not seem to be dose-related (Ref)

Gastrointestinal hypomotility

Clozapine-induced decreased gastrointestinal motility is common and may result in delayed gastric emptying, GI dysmotility (small bowel or colon), and constipation (the cardinal feature), but it may also progress to severe and potentially life-threatening events, including fecal impaction, non-Hirschsprung megacolon, paralytic ileus, intestinal obstruction, gastrointestinal infarction (including ischemia), gastrointestinal necrosis, and gastrointestinal perforation. Mortality related to serious GI hypomotility events is high and may be as high as 12-fold that of agranulocytosis. Preventative measures are recommended for constipation (Ref).

Mechanism: Not been fully elucidated but has been mainly attributed to clozapine’s anticholinergic and antiserotonergic effects. Clozapine antagonizes cholinergic M1 and M3 receptors which can interfere with autonomic regulation of the intestine, inhibitor smooth muscle contraction, and slow intestinal transit. Antagonism of serotonin 5-HT2, 5-HT3, 5-HT6, and 5-HT7 receptors also play a role in GI motor and sensory functions (Ref). Antiadrenergic effects may also play a role (Ref).

Risk factors:

• Older adults (Ref)

• Concomitant use of anticholinergics and other medications that decrease GI peristalsis (Ref)

• Higher daily doses (Ref)

Hepatic effects

Increased serum hepatic transaminases are common with use, including elevations 2 to 3 times greater than normal. Increased liver enzymes are usually transient and asymptomatic, with the majority not requiring discontinuation or a dose reduction unless elevations are persistent and/or accompanied by symptoms. However, there have been rare case reports of severe hepatotoxicity including hepatitis, acute hepatotoxicity, and fulminant hepatic failure (including fatal cases) (Ref)

Mechanism: Unknown; although, clozapine is extensively metabolized by the liver, partially via the cytochrome P450 pathway, including CYP1A2 (Ref).

Onset: Varied; increased transaminases usually occur within first several weeks following initiation and most resolve after 6 to 12 weeks; in the case reports describing serious hepatic events, onset is typically within a few days to several weeks (ie, 4 to 6 weeks) following initiation (Ref)

Hyperglycemia

Clozapine is strongly associated with hyperglycemia, which is a component of the metabolic syndrome observed with this pharmacologic class. Glycemic abnormalities range from mild insulin resistance to new-onset diabetes mellitus, exacerbation of diabetes mellitus, hyperosmolar coma, and diabetic ketoacidosis (DKA), including fatal cases (Ref). A 10-year naturalistic study of clozapine-treated adult patients suggested an increased risk of mortality from cardiovascular disease (CVD) secondary to disorders such as obesity, diabetes, hypertension, and hyperlipidemia; however, patients with schizophrenia have a higher risk of CVD than the general population due to lifestyle habits (eg, smoking, physical inactivity, unhealthy diet), regardless of medication use (Ref).

Mechanism: The mechanism is not entirely understood and is likely multifactorial (Ref).

Onset: Varied; new-onset diabetes has been observed within the first 3 months to a median onset of 3.9 years of antipsychotics (Ref). In a review of clozapine-associated diabetes reports, most cases of hyperglycemia appeared within 6 months of initiation (Ref). Clozapine-related DKA typically occurs early in the treatment course (Ref).

Risk factors:

• African American race (Ref)

• Males (Ref)

• Age <35 years (Ref)

• Patients with preexisting obesity, poor exercise habits, or other risk factors for diabetes, including family history of diabetes (Ref)

• Exposures to other agents that also increase the risk of hyperglycemia (Ref)

• Treatment duration (Ref)

• Specific antipsychotic: Risk of metabolic disturbances appears to be high with clozapine (Ref).

Mortality in older patients

Older adults with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature (Ref). For clozapine, several large epidemiological cohort studies in mostly schizophrenia patients have found an association between clozapine and lower all-cause mortality; however, these studies were not exclusive to older adults and the median or mean age at the start of the study ranging from 36 to 49 years of age (Ref). In a retrospective analysis of older adults >60 years of age (mean age: 70 years) with treatment-resistant schizophrenia treated with clozapine, mortality was found to be similar with clozapine compared to other first- and second-generation antipsychotics (Ref). In addition, an increased incidence of cerebrovascular effects (eg, cerebrovascular accident, transient ischemic attacks), including fatalities, have been reported in some second-generation antipsychotic placebo-controlled trials, such as risperidone and olanzapine, in older adults with dementia-related psychosis (Ref). Of note, clozapine is not approved for the treatment of dementia-related psychosis.

Mechanism: Unknown; possible mechanisms include arrhythmia, cardiac arrest, and extrapyramidal effects that may increase the risk of falls, aspiration, and pneumonia (Ref).

Risk factors:

• Higher antipsychotic dosage (Ref)

• Dementia-related psychosis (eg, Lewy body dementia, Parkinson disease dementia)

• Older adults

Myocarditis/cardiomyopathy

Clozapine-induced myocarditis and pericarditis are rare/infrequent but potentially fatal adverse events, typically occurring early in the course of therapy (ie, first 1 to 2 months) with ensuing clozapine-induced cardiomyopathy typically presenting later during therapy. Clinical signs and symptoms are highly variable and range from asymptomatic to nonspecific signs such as fever, chest pain, hypotension, flu-like symptoms, eosinophilia, elevated C-reactive protein, increased troponin, ECG changes, signs of heart failure, palpitations, dyspnea, and/or sinus tachycardia. Clozapine-induced myocarditis is associated with high mortality if not recognized early; prompt therapy discontinuation is required to prevent disease progression (Ref). Cases of sudden cardiac death subsequently identified on autopsy as myocarditis with eosinophilic infiltrates have also been reported in patients newly initiated on clozapine (Ref).

Mechanism: Unclear; however, several hypotheses have been proposed for clozapine-induced cardiotoxicity, including a type 1 acute hypersensitivity reaction mediated by Ig-E, a pro-inflammatory cytokine pathway involving TNF-alpha, and a hypercatecholaminergic state contributing to increased production of free radicals and subsequent oxidative stress (Ref). A role of viral infections has also been suggested (Ref).

Onset: Varied; myocarditis usually occurs within the first 8 weeks of therapy and cardiomyopathy usually presents months or years after therapy (Ref).

Risk factors:

• Rapid titration and higher doses early in clozapine titration (potential risk factor) (Ref)

• Concomitant sodium valproate (potential risk factor) (Ref)

• Patients living in Australia or New Zealand (potential risk factor). Note: Although event rates are higher in Australia and New Zealand, it is unknown if this is due to observation bias or unidentified genetic and/or environmental factors (Ref)

Neuroleptic malignant syndrome

All antipsychotics have been associated with neuroleptic malignant syndrome (NMS), although the incidence is less with second-generation (atypical) antipsychotics compared to first-generation (typical) antipsychotics. There are case reports of NMS with clozapine, including monotherapy. Furthermore, clozapine-associated NMS may present with atypical features, such as absent or less intense rigidity, fever, and/or fewer extrapyramidal symptoms in general (Ref).

Mechanism: Non–dose-related; idiosyncratic. Believed to be due to a reduction in CNS dopaminergic tone, along with the dysregulation of autonomic nervous system activity (Ref).

Onset: Varied; in general, most patients develop NMS within 2 weeks of initiating an antipsychotic, and in some patients, prodromal symptoms emerge within hours of initiation; once the syndrome starts, the full syndrome usually develops in 3 to 5 days (Ref). However, there are many cases of NMS occurring months or even years after stable antipsychotic therapy, including clozapine treatment (Ref).

Risk factors:

Antipsychotics in general:

• Males are twice as likely to develop NMS compared to females (Ref)

• Dehydration (Ref)

• High-dose antipsychotic treatment (Ref)

• Concomitant lithium or a benzodiazepine (potential risk factors) (Ref)

• Catatonia (Ref)

• Disorganized speech or behavior (Ref)

• Polypharmacy (Ref)

• Pharmacokinetic interactions (Ref)

• IM administration of an antipsychotic (Ref)

• Rapid dosage escalation (Ref)

• Psychomotor agitation (Ref)

Orthostatic hypotension

Clozapine commonly causes significant orthostatic hypotension and accompanying reflex tachycardia, bradycardia, and dizziness in adults, particularly with rapid titration. Older adults are especially vulnerable to orthostatic hypotension, and coupled with clozapine’s sedative properties, these effects increase the risk for subsequent falling. Once the dose is stabilized, giving the full dose or the majority of the full daily dose at bedtime may help reduce risk of orthostatic hypotension. If therapy is interrupted even for a brief interval (≥2 days), therapy should be retitrated to reduce the risk of orthostatic hypotension. Of note, tachycardia, not limited to reflex tachycardia, is also common with clozapine therapy (Ref).

Mechanism: Dose-related; orthostatic hypotension is attributed to alpha-1 adrenergic receptor antagonism (Ref).

Onset: Rapid; per the manufacturer's labeling, risk of orthostatic hypotension is highest during the initial dose titration but can also occur following reinitiation of therapy after periods of interrupted therapy and/or subsequent dose increases.

Risk factors:

• Known cardiovascular diseases (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities) or cerebrovascular disease

• Known predisposing conditions (eg, hypovolemia/dehydration)

• Concomitant medications that also cause or exacerbate orthostatic hypotension (eg, tricyclic antidepressants, antihypertensive medications)

• Older adults (due to reduced autonomic function) (Ref)

• Rapid dose titration (slow titration is recommended) (Ref)

• Higher doses (ie, temporarily lowering the dose may help manage orthostatic hypotension) (Ref)

QTc prolongation

Clozapine has been associated with dose-dependent prolonged QT interval on ECG. In general, clozapine’s effect on QTc prolongation is typically benign in patients without additional risk factors (Ref). The risk for torsades de pointes (TdP) is considered to be possible, but evidence supporting causality is lacking (Ref). In a review of reports of QTc prolongation and/or TdP associated with clozapine at therapeutic doses, the vast majority of QTc prolongation cases (and both the TdP cases) were confounded by concomitant risk factors (eg, comedications known to prolong the QTc interval, comorbidities). Similarly, many reports of sudden death associated with clozapine therapy occurred in a setting of potentially confounding factors (Ref). Of note, clozapine is also associated with other cardiac effects, such as myocarditis and cardiomyopathy, which may also play a role in risk for QTc prolongation and/or sudden death (Ref).

Mechanism: Dose-dependent; clozapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current (Ikr); however, clozapine also interacts with multiple receptors including dopamine, adrenergic, serotonin, muscarinic, and histamine, which may balance or mitigate its effect on the HERG K+ channel. Clozapine also affects heart rate which may influence QTc determination (Ref).

Risk factors:

Drug-induced QTc prolongation/TdP (in general):

• Females (Ref)

• Age >65 years (Ref)

• Structural heart disease (eg, history of myocardial infarction or heart failure with a reduced ejection fraction) (Ref)

• History of drug-induced TdP (Ref)

• Genetic defects of cardiac ion channels (Ref)

• Congenital long QT syndrome (Ref)

• Baseline QTc interval prolongation (eg, >500 msec) or lengthening of the QTc by ≥60 msec (Ref)

• Electrolyte disturbances (eg, hypokalemia, hypocalcemia, hypomagnesemia) (Ref)

• Bradycardia (Ref)

• Hepatic impairment (Ref)

• Kidney impairment (Ref)

• Co-administration of multiple medications (≥2) that prolong the QT interval or increase drug interactions that increase serum drug concentrations of QTc prolonging medications (Ref)

• Substance use (Ref)

Sedation

Sedated state (drowsiness) is common with use and may cause nonadherence, impair physical and mental abilities, and may result in subsequent falling, particularly in older adults (Ref). Most patients tolerate sedation within 6 weeks of therapy initiation; however, it may persist in many patients, particularly older adults (Ref).

Mechanism: Sedation is primarily attributed to H1 antagonism; clozapine is considered to have high affinity for H1 receptors (Ref).

Risk factors:

• Older adults (sedation may be persistent rather than transient in this population) (Ref)

• Higher doses (potential risk factor but not conclusive since a dose-reduction does not always mitigate effect) (Ref)

• Specific antipsychotic: Clozapine is considered highly sedating (Ref)

Seizures or myoclonus

Clozapine is strongly associated with dose-dependent seizure. Clozapine also commonly causes EEG pattern changes. Tonic-clonic seizure is the most commonly described seizure with clozapine use followed by myoclonic seizure and atonic seizure. Myoclonus has also been reported in several case reports (Ref).

Mechanism: Dose-dependent (although exact dose-relationship is unclear); precise mechanism is unclear, although a role of inhibiting D4 (dopamine) mesolimbic and cortical receptors has been suggested. Other possible mechanisms have been suggested, such as interactions with NMDA, GABA, and glutamate receptors (Ref).

Risk factors:

• Specific antipsychotic: Among the second-generation antipsychotics, clozapine appears to have the highest risk of seizure induction (Ref)

• Higher doses (doses >600 mg/day have been historically associated with increased risk of seizure, although seizures have been reported with doses as low as 200 to 300 mg/day) (Ref)

Antipsychotics in general:

• History of seizure activity (Ref)

• Concurrent use of drugs that lower seizure threshold (Ref)

• Rapid dose titration or sudden increase in dose (Ref)

• Slow drug metabolism (Ref)

• Metabolic factors (Ref)

• Drug-drug interactions (Ref)

• Organic brain disorders (Ref)

Severe neutropenia/agranulocytosis

Clozapine may cause severe neutropenia (ANC <500/mm3) and potentially life-threatening agranulocytosis (ANC <100/mm3) in adult and pediatric patients (Ref). Due to the risk, baseline and regular ANC monitoring is recommended. Patients with Duffy-null neutropenia are not at increased risk for developing clozapine-induced severe neutropenia and frequently have ANC values in the typical neutropenia range (Ref).

Mechanism: Non–dose-related; idiosyncratic. Mechanism has not been fully elucidated, although an immune-mediated mechanism has been proposed. Clozapine has a high potential to undergo oxidative degradation and form nitrenium ion. The nitrenium ion may cause direct toxicity or stimulate an immune response following covalent binding to human leukocytes and forming an antigen (Ref).

Onset: Varied; clozapine-induced agranulocytosis typically occurs in the first 18 weeks of therapy, with a few cases developing after 6 months of use. Risk is further decreased after 1 year of treatment (Ref).

Risk factors:

• History of drug-induced neutropenia or preexisting low WBC or ANC

• Age between 40 and 59 years (Ref). Note: It has also been suggested that children and adolescents are at increased risk for neutropenia (Ref)

• Males (Ref)

• White ethnicity (Ref). Note: It has also been suggested that Asian ethnicities may be at a higher risk for agranulocytosis, and African American and Middle Eastern ethnicities may have a higher risk for Duffy-null neutropenia (Ref)

• Genetic variants of several genes (eg, HLA-B alleles with a threonine at position 158 in the protein sequence [HLA-B*38,39,67]), although further studies are needed (Ref)

Sialorrhea

Clozapine-induced sialorrhea, also known as hypersalivation or drooling, is common, may be severe, and may cause nonadherence. It can occur during the daytime but is typically much worse during sleep and may result in choking sensations during the night, nighttime awakening, hoarseness or dysphonia of the voice, and a chronic cough. Clozapine-induced sialorrhea may contribute to and increase the risk of potentially life-threatening aspiration pneumonia (Ref).

Mechanism: Dose-related (potentially); mechanism is unclear although it is believed to be due to muscarinic M4 receptor agonism, alpha-2 adrenergic receptor antagonism, as well as alterations in the swallowing reflex and a decrease in laryngeal peristalsis. M1 agonism by the N-desmethylclozapine metabolite has also been postulated (Ref).

Risk factors:

• Rapid titration (titrate slowly to reduce risk)

• Higher doses (potential risk factor). Note: Conflicting evidence exists on whether this is dose-related or not; however, a dose reduction may be considered to mitigate symptoms (Ref)

• Extremes of age (may be more sensitive to complications from sialorrhea) (Ref)

Temperature dysregulation

Antipsychotics, including clozapine, may cause disruption of body temperature regulation, which may cause a potentially life-threatening heatstroke during predisposing conditions such as a heat wave or strenuous exercise (Ref). There are also a numerous case reports of potentially life-threatening hypothermia associated with clozapine use (Ref).

Mechanism: Non–dose-related; idiosyncratic. Exact mechanism is unknown; however, body temperature is regulated by the hypothalamus with involvement of the dopamine, serotonin, and norepinephrine neurotransmitters. D2 antagonism may cause an increase in body temperature, while 5-HT2a (serotonin) receptor antagonism may cause a decrease in body temperature. Of note, clozapine has a stronger affinity for serotonin 5-HT2a receptors compared to D2 receptors where it displays a much lower affinity. Clozapine and its metabolite, N-desmethylclozapine, bind to many different receptors so it is also likely that other mechanisms are involved. In addition, antagonism of peripheral alpha-2 adrenergic receptors has also been suggested as a factor in the hypothermic effect by inhibiting peripheral responses to cooling (vasoconstriction and shivering) (Ref).

Onset: Hypothermia: Varied; antipsychotic-induced hypothermia cases indicate a typical onset in the period shortly after initiation of therapy or a dosage increase (first 7 to 10 days) (Ref). In clozapine hypothermia case reports, the majority occurred within the first month, but some cases have developed years after initiation (Ref).

Risk factors:

Heat stroke:

• Psychiatric illness (regardless of medication) (Ref)

• Strenuous exercise, heat exposure, and dehydration (Ref)

• Concomitant medication possessing anticholinergic effects (Ref)

Hypothermia:

• In general, predisposing risk factors include: Older age, cerebrovascular accident, preexisting brain damage, hypothyroidism, malnutrition, shock, sepsis, adrenal insufficiency, diabetes, disability, burns, exfoliative dermatitis, benzodiazepine use, alcohol intoxication, kidney or liver failure (Ref)

• Schizophrenia (regardless of antipsychotic use) (Ref)

Venous thromboembolism

Multiple cases reports and case series of deep vein thrombosis (DVT) and pulmonary embolism (PE) (some fatal) have been associated with clozapine therapy (Ref). There is also a case report of an upper-extremity deep vein thrombosis (UEDVT) in a patient with a prothrombin mutation (Ref) and a case report of a cerebral venous thrombosis, a potentially life-threatening event, in a patient receiving clozapine (Ref).

Mechanism: Likely multifactorial; clozapine-associated sedation, obesity, and a sedentary lifestyle may increase the risk for DVT via venous stasis. Of note, independent of drug therapy, obesity is associated with inflammation and hypercoagulability and psychiatric disorders are associated with a sedentary lifestyle. In addition, clozapine's affinity for serotonin 5-HT2A receptors may affect platelet aggregation. It has also been suggested that clozapine may also have an effect on activated partial thromboplastin time, antiphospholipid antibodies, and C-reactive protein, although more research is needed (Ref).

Onset: Varied; in a systematic review of PE case reports, the authors found the highest incidence within the first 6 months of treatment (Ref); however, in another systemic review PE cases, the authors describe an anywhere from a few days to several years after initiation of therapy (Ref).

Risk factors:

DVT/PE, in general:

• Obesity (Ref)

• Genetic factors (eg, factor V Leiden mutation) (Ref)

• Gynecologic/pelvic surgery (Ref)

• Indwelling venous catheter (Ref)

• Pregnancy (Ref)

• Malignancy (Ref)

• Drugs such as oral contraceptives (Ref)

• Recent immobility (Ref)

• Recent surgery (Ref)

• Major trauma (Ref)

Weight gain

Clozapine is strongly associated with significant weight gain (increase of ≥7% from baseline) in children, adolescents, and adults, which is a component of the metabolic syndrome observed with this pharmacologic class (Ref). A 10-year naturalistic study of clozapine-treated adult patients suggested an increased risk of mortality from cardiovascular disease secondary to disorders such as obesity, diabetes, hypertension, and hyperlipidemia; however, patients with schizophrenia have a higher risk of cardiovascular disease than the general population due to lifestyle habits (eg, smoking, physical inactivity, unhealthy diet), regardless of medication use (Ref).

Mechanism: Multiple proposed mechanisms, including actions at serotonin, dopamine, histamine, and muscarinic receptors, with differing effects on weight gain by the different antipsychotic agents explained by differing affinity at these receptors (Ref).

Onset: Varied; antipsychotic-induced weight gain usually occurs rapidly in the period following initiation, then gradually decreases and flattens over several months with patients continuing to gain weight in the long term; the time before weight begins to plateau varies by antipsychotic, with a time of 42 to 46 months for clozapine before weight beings to plateau (Ref).

Risk factors:

• Genetic polymorphisms (some evidence suggests that clozapine-induced weight gain is associated with polymorphisms in genes encoding leptin, leptin receptor, and the serotonin receptor HTR2C) (Ref)

• Family history of obesity (Ref)

• Parental BMI (Ref)

• Children and adolescents (antipsychotics in general; data are lacking to suggest there is a disproportionately higher weight gain with clozapine in this population compared to adults) (Ref)

• Factors associated with rapid weight gain in the initial period: Younger age, lower BMI, more robust response to antipsychotic, and increase in appetite; rapid weight gain of >5% in the first month has been observed as the best predictor for significant long-term weight gain (Ref)

• Duration of therapy (although weight gain plateaus, patients continue to gain weight over time) (Ref)

• Schizophrenia (regardless of medication) is associated with a higher prevalence of obesity compared to the general population due to components of the illness, such as negative symptoms, sedentary lifestyles, and unhealthy diets (Ref)

• Specific antipsychotic: Clozapine is considered to have a high propensity for causing weight gain (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Cardiovascular: Hypertension (4% to 12%), hypotension (9% to 13%), tachycardia (17% to 25%) (table 1)

Clozapine: Adverse Reaction: Tachycardia

Drug (Clozapine)

Comparator (Chlorpromazine)

Indication

Number of Patients (Clozapine)

Number of Patients (Chlorpromazine)

17%

11%

Treatment-resistant schizophrenia

126

142

25%

N/A

N/A

842

N/A

Endocrine & metabolic: Hypercholesterolemia (8% to 38%) (table 2), hyperglycemia (27% to 42%) (table 3), hypertriglyceridemia, weight gain (4% to 31%)

Clozapine: Adverse Reaction: Hypercholesterolemia

Drug (Clozapine)

Comparator (Chlorpromazine)

Indication

Number of Patients (Clozapine)

Number of Patients (Chlorpromazine)

Comments

38%

41%

Schizophrenia

79

34

Change (at least once) from baseline: Borderline (200 to 239 mg/dL) to high (≥240 mg/dL)

8%

2%

Schizophrenia

222

132

Change (at least once) from baseline: Normal (<200 mg/dL) to high (≥240 mg/dL)

Clozapine: Adverse Reaction: Hyperglycemia

Drug (Clozapine)

Comparator (Chlorpromazine)

Indication

Number of Patients (Clozapine)

Number of Patients (Chlorpromazine)

Comments

42%

28%

Schizophrenia

57

43

Change (at least once) from baseline in fasting blood glucose: Borderline (100 to 125 mg/dL) to high (≥126 mg/dL)

27%

10%

Schizophrenia

198

135

Change (at least once) from baseline in fasting blood glucose: Normal (<100 mg/dL) to high (≥126 mg/dL)

Gastrointestinal: Constipation (14% to 25%) (table 4), dyspepsia (14%), nausea (≤17%), sialorrhea (13% to 48%) (table 5), vomiting (≤17%)

Clozapine: Adverse Reaction: Constipation

Drug (Clozapine)

Comparator (Chlorpromazine)

Comparator (Olanzapine)

Indication

Number of Patients (Clozapine)

Number of Patients (Comparator)

25%

N/A

10%

Suicidal behavior in schizophrenia or schizoaffective disorder

479

477

16%

12%

N/A

Treatment-resistant schizophrenia

126

142

14%

N/A

N/A

N/A

842

N/A

Clozapine: Adverse Reaction: Sialorrhea

Drug (Clozapine)

Comparator (Chlorpromazine)

Comparator (Olanzapine)

Indication

Number of Patients (Clozapine)

Number of Patients (Comparator)

48%

N/A

6%

Suicidal behavior in schizophrenia or schizoaffective disorder

479

477

13%

1%

N/A

Treatment-resistant schizophrenia

126

142

31%

N/A

N/A

N/A

842

N/A

Nervous system: Dizziness (14% to 27%) (table 6), drowsiness (≤46%) (table 7), insomnia (2% to 20%), sedated state (≤39%) (table 8), vertigo (≤19%)

Clozapine: Adverse Reaction: Dizziness

Drug (Clozapine)

Comparator (Chlorpromazine)

Comparator (Olanzapine)

Indication

Number of Patients (Clozapine)

Number of Patients (Comparator)

Comments

27%

N/A

12%

Suicidal behavior in schizophrenia or schizoaffective disorder

479

477

N/A

14%

16%

N/A

Treatment-resistant schizophrenia

126

142

N/A

19%

N/A

N/A

N/A

842

N/A

Defined as "dizziness/vertigo"

Clozapine: Adverse Reaction: Drowsiness

Drug (Clozapine)

Comparator (Olanzapine)

Indication

Number of Patients (Clozapine)

Number of Patients (Olanzapine)

Comments

46%

25%

Suicidal behavior in schizophrenia or schizoaffective disorder

479

477

N/A

39%

N/A

N/A

842

N/A

Defined as "drowsiness/sedation"

Clozapine: Adverse Reaction: Sedated State

Drug (Clozapine)

Comparator (Chlorpromazine)

Indication

Number of Patients (Clozapine)

Number of Patients (Chlorpromazine)

Comments

21%

13%

Treatment-resistant schizophrenia

126

142

N/A

39%

N/A

N/A

842

N/A

Defined as "drowsiness/sedation"

Miscellaneous: Fever (5% to 13%) (table 9)

Clozapine: Adverse Reaction: Fever

Drug (Clozapine)

Comparator (Chlorpromazine)

Indication

Number of Patients (Clozapine)

Number of Patients (Chlorpromazine)

13%

4%

Treatment-resistant schizophrenia

126

142

5%

N/A

N/A

842

N/A

1% to 10%:

Cardiovascular: Syncope (6%)

Dermatologic: Diaphoresis (6%), skin rash (2%)

Gastrointestinal: Abdominal distress (≤4%), diarrhea (2%), heartburn (≤4%), xerostomia (5% to 6%) (table 10)

Clozapine: Adverse Reaction: Xerostomia

Drug (Clozapine)

Comparator (Chlorpromazine)

Indication

Number of Patients (Clozapine)

Number of Patients (Chlorpromazine)

5%

20%

Treatment-resistant schizophrenia

126

142

6%

N/A

N/A

842

N/A

Genitourinary: Urine abnormality (2%)

Hematologic & oncologic: Eosinophilia (1%), leukopenia (≤3%), neutropenia (≤3%)

Nervous system: Agitation (4%), akathisia (3%), akinesia (≤4%), confusion (3%), fatigue (2%), headache (7% to 10%), nightmares (≤4%), restlessness (4%), seizure (3%), sleep disturbance (≤4%), tremor (6%)

Neuromuscular & skeletal: Hypokinesia (≤4%), muscle rigidity (3%)

Ophthalmic: Visual disturbance (5%)

Frequency not defined:

Cardiovascular: Bradycardia, orthostatic hypotension

Nervous system: Tardive dyskinesia

Postmarketing:

Cardiovascular: Acute myocardial infarction (Ref), atrial fibrillation (Ref), cardiomyopathy (Ref), deep vein thrombosis (including upper extremity deep vein thrombosis) (Ref), mitral valve insufficiency, myocarditis (Ref), palpitations (Ref), pericarditis (Ref), prolonged QT interval on ECG (Ref), pulmonary embolism (Ref), sinus tachycardia (Ref), supraventricular tachycardia (Ref), torsades de pointes, ventricular ectopy (Ref), ventricular fibrillation, ventricular tachycardia

Dermatologic: Dermatologic reaction (symmetrical drug-related intertriginous and flexural exanthema [SDRIFE]) (Ref), dyschromia, erythema multiforme, skin photosensitivity, Stevens-Johnson syndrome (Ref), urticaria (cholinergic) (Ref)

Endocrine & metabolic: Diabetes mellitus (Ref), diabetes mellitus with hyperosmolar coma, diabetic ketoacidosis (Ref), exacerbation of diabetes mellitus (Ref), heatstroke (Ref), hyperuricemia, hyponatremia, increased libido (Ref), pheochromocytoma (pseudo) (Ref), weight loss

Gastrointestinal: Acute pancreatitis (Ref), appendicitis (Ref), cholestasis, colitis (including Clostridioides difficile colitis, necrotizing enterocolitis, neutropenic enterocolitis) (Ref), decreased GI motility (literature suggests an incidence of 31%) (Ref), dysphagia, esophagitis (Ref), fecal impaction (Ref), fecal incontinence, gastrointestinal reflux disease (Ref), gastrointestinal infarction, gastrointestinal necrosis (Ref), gastrointestinal perforation (Ref), gastrointestinal ulcer, intestinal obstruction, mesenteric ischemia (Ref), non-Hirschsprung megacolon, paralytic ileus, peritonitis (Ref), sialadenitis (parotitis) (Ref)

Genitourinary: Nocturnal enuresis (Ref), priapism (Ref), retrograde ejaculation, urinary incontinence (Ref)

Hematologic & oncologic: Agranulocytosis (literature suggests an incidence up to 1% to 2%) (Ref), anemia (Ref), granulocytopenia, hyperleukocytosis (Ref), increased erythrocyte sedimentation rate, increased hematocrit, increased hemoglobin, leukemia (Ref)), lymphocytopenia (Ref), malignant lymphoma (Ref), thrombocytopenia (Ref), thrombocytosis (Ref)

Hepatic: Acute hepatotoxicity (Ref), hepatic cirrhosis, hepatic failure (Ref), hepatic fibrosis, hepatic necrosis (Ref), hepatitis (including cholestatic hepatitis, fulminant hepatitis) (Ref), hepatotoxicity (Ref), increased liver enzymes (Ref), jaundice (Ref), liver steatosis

Hypersensitivity: Angioedema (Ref), drug reaction with eosinophilia and systemic symptoms (Ref), hypersensitivity angiitis (Ref), hypersensitivity reaction (Ref)

Infection: Infection (Ref), sepsis (Ref)

Nervous system: Abnormal electroencephalogram (Ref), cataplexy, cerebral thrombosis (venous) (Ref), cognitive dysfunction (Ref), delirium (Ref), disruption of body temperature regulation (Ref), drug withdrawal (including catatonia) (Ref), EEG pattern changes (literature suggests an incidence of 63%) (Ref), hypothermia (Ref), myasthenia, myoclonus (Ref), neuroleptic malignant syndrome (Ref), obsessive compulsive disorder (symptoms) (Ref), paresthesia, restless leg syndrome, status epilepticus, stuttering (Ref)

Neuromuscular & skeletal: Dystonia (acute) (Ref), increased creatine phosphokinase in blood specimen, rhabdomyolysis (Ref), systemic lupus erythematosus

Ophthalmic: Angle-closure glaucoma, periorbital edema (Ref)

Renal: Acute interstitial nephritis (Ref), kidney failure (Ref)

Respiratory: Lower respiratory tract infection, pleural effusion (Ref), pneumonia (Ref), pneumonitis (Ref), pulmonary aspiration (Ref), sleep apnea (including obstructive sleep apnea syndrome (Ref))

Miscellaneous: Polyserositis (Ref)

Contraindications

Serious hypersensitivity to clozapine or any component of the formulation (eg, photosensitivity, vasculitis, erythema multiforme, or Stevens-Johnson syndrome [SJS])

Canadian labeling: Additional contraindications (not in US labeling): Myeloproliferative disorders; history of toxic or idiosyncratic agranulocytosis or severe granulocytopenia (unless due to previous chemotherapy); concomitant use with other agents that suppress bone marrow function; active hepatic disease associated with nausea, anorexia, or jaundice; progressive hepatic disease or hepatic failure; paralytic ileus; uncontrolled epilepsy; severe CNS depression or comatose states; severe renal impairment; severe cardiac disease (eg, myocarditis); patients unable to undergo blood testing

Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Warnings/Precautions

Concerns related to adverse effects:

• Suicidal ideation: The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder; use with caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.

Disease-related concerns:

• Acute infectious/inflammatory processes: Elevation of serum clozapine levels have been reported in the setting of acute infection or inflammatory process. Reactions ranging from mild sedation to symptoms requiring an ICU level of care have been reported. Significant increases of serum levels do not always correlate with clinical signs and symptoms of clozapine toxicity. Signs and symptoms such as hypotension, sialorrhea, and sedation that cannot be explained by other medications or conditions may necessitate a temporary dose reduction or discontinuation, depending on the severity (Clark 2017; Leung 2014).

• Bariatric surgery: Presurgical assessment of the indication for use, symptoms, and goals of therapy should be documented to enable postsurgical assessment. Clozapine is strongly associated with significant weight gain (Alonso-Pedrero 2019; Citrome 2011; Dayabandara 2017; De Hert 2011b). If this medication is being used after bariatric surgery, monitor weight closely postoperatively and consider changing agent to alternative agent if weight loss goals are not being met.

• GI motility: Use with caution in patients with decreased GI motility as anticholinergic effects may exacerbate underlying condition.

• Hepatic impairment: Use with caution in patients with hepatic disease or impairment; monitor hepatic function regularly. Dosage reduction may be necessary in patients with significant hepatic impairment.

• Ophthalmic conditions: Use with caution in patients with certain ophthalmic conditions (eg, visual problems) as anticholinergic effects may exacerbate underlying condition.

• Renal impairment: Use with caution in patients with renal impairment. Dosage reduction may be necessary in patients with significant renal impairment.

• Urinary retention (eg, benign prostatic hyperplasia): Use with caution in patients with urinary retention as anticholinergic effects may exacerbate underlying condition.

Special populations:

• CYP2D6 poor metabolizers: Clozapine concentrations may be increased in CYP2D6 poor metabolizers. Dose reduction may be necessary.

• Older adult: The older adult patients are more susceptible to adverse effects. Older adult patients may be at increased risk of seizures due to an increased prevalence of predisposing factors (Gareri 2008).

• Smokers: Clozapine levels may be lower in patients who smoke. Smokers may require twice the daily dose as nonsmokers in order to obtain an equivalent clozapine concentration (Tsuda 2014). Smoking cessation may cause toxicity in a patient stabilized on clozapine. Monitor change in smoking patterns. Consider baseline serum clozapine levels and/or empiric dosage adjustments (30% to 40% reduction) in patients expected to have a prolonged hospital stay with forced smoking cessation. Case reports suggest symptoms from increasing clozapine concentrations may develop 2 to 4 weeks after smoking cessation (Lowe 2010).

Dosage form specific issues:

• Brand/generic: Use caution when converting from brand to generic formulation; poor tolerability, including relapse, has been reported usually soon after product switch (1 to 3 months); monitor closely during this time (Bobo 2010).

• Phenylalanine: Oral disintegrating tablets may contain phenylalanine.

Other warnings/precautions:

• Discontinuation of therapy: In general, when discontinuing antipsychotic therapy, gradually taper antipsychotics to avoid physical withdrawal symptoms and rebound symptoms (APA [Keepers 2020]; WFSBP [Hasan 2012]); the manufacturer recommends reducing the clozapine dose gradually over a period of 1 to 2 weeks if termination of therapy is not related to neutropenia. Withdrawal symptoms may include agitation, alternating feelings of warmth and cold, anxiety, diaphoresis, dyskinesia, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, and vertigo (Lambert 2007; Moncrieff 2020). The risk of withdrawal symptoms is highest following abrupt discontinuation of highly anticholinergic or dopaminergic antipsychotics (Cerovecki 2013). Patients with chronic symptoms, repeated relapses, and clear diagnostic features of schizophrenia are at risk for poor outcomes if medications are discontinued (APA [Keepers 2020]).

Warnings: Additional Pediatric Considerations

Similar to adult experience, the American Academy of Child and Adolescent Psychiatry (AACAP) guidelines recommend gradually tapering antipsychotics to avoid discontinuation symptoms and minimize the risk of relapse (AACAP [McClellan 2007]).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Suspension, Oral:

Versacloz: 50 mg/mL (100 mL) [contains methylparaben sodium, propylparaben sodium]

Tablet, Oral:

Clozaril: 25 mg [contains corn starch]

Clozaril: 50 mg [DSC] [scored; contains corn starch]

Clozaril: 100 mg, 200 mg [DSC] [contains corn starch]

Generic: 25 mg, 50 mg, 100 mg, 200 mg

Tablet Disintegrating, Oral:

Generic: 12.5 mg, 25 mg, 100 mg, 150 mg, 200 mg

Generic Equivalent Available: US

May be product dependent

Pricing: US

Suspension (Versacloz Oral)

50 mg/mL (per mL): $10.13

Tablet, orally-disintegrating (cloZAPine Oral)

12.5 mg (per each): $2.23

25 mg (per each): $3.00

100 mg (per each): $8.18

150 mg (per each): $20.72

200 mg (per each): $27.62

Tablets (cloZAPine Oral)

25 mg (per each): $0.43 - $1.32

50 mg (per each): $1.32 - $1.65

100 mg (per each): $1.12 - $3.43

200 mg (per each): $2.46 - $6.32

Tablets (Clozaril Oral)

25 mg (per each): $7.60

100 mg (per each): $19.69

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Clozaril: 25 mg, 50 mg, 100 mg, 200 mg

Generic: 25 mg, 50 mg, 100 mg, 200 mg

Prescribing and Access Restrictions

Canada: Currently, there are multiple manufacturers that distribute clozapine and each manufacturer has its own registry and distribution system. Patients must be registered in a database that includes their location, prescribing physician, testing laboratory, and dispensing pharmacist before using clozapine. Patients may not be switched from one brand of clozapine to another without completion of a new registry-specific patient registration form by signed by the prescribing physician. Information specific to each monitoring program is available from the individual manufacturers.

Administration: Adult

Oral: Administer without regard to food. Total daily dose may be divided into uneven doses with larger dose administered at bedtime.

Orally disintegrating tablet: Remove from foil blister by peeling apart (do not push tablet through the foil). Remove immediately prior to use. Place tablet in mouth and chew or allow to dissolve; swallow with saliva. If dosing requires splitting tablet, throw unused portion away.

Suspension: Shake bottle prior to use. Using syringe adaptor and oral syringe provided withdrawal dose from bottle. Administer immediately after preparation using the oral syringe provided.

Administration: Pediatric

Oral: May be administered without regard to food. Total daily dose may be divided into uneven doses with larger dose administered at bedtime.

Orally disintegrating tablet: Immediately prior to use, gently remove the tablet from the bottle or blister package by peeling the foil from the blister (do not push tablet through the foil). Upon removing, place tablet in mouth; it may be allowed to dissolve, chewed, or swallowed with saliva (no water is needed). If dosing requires splitting tablet, throw unused portion away.

Oral suspension: Oral syringes, a bottle neck adaptor should be provided. Appropriate syringe size dependent upon dose: Use the 1-mL syringe for doses ≤50 mg and the 9-mL syringe for doses >50 mg.

Shake the bottle for 10 seconds, then remove the cap. For the first use of the bottle, after removing the cap, push the adaptor into the top of the bottle. Once dose is withdrawn from the bottle, it should be administered immediately and not stored for later use. After use, re-cap the bottle and rinse the syringe with water.

Use: Labeled Indications

Schizophrenia, treatment resistant and Suicidality in schizophrenia or schizoaffective disorder:

Schizophrenia, treatment resistant: Treatment of severely ill patients with schizophrenia who fail to respond adequately to antipsychotic treatment.

Suicidal behavior in schizophrenia or schizoaffective disorder: To reduce the risk of suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for reexperiencing suicidal behavior, based on history and recent clinical state.

Use: Off-Label: Adult

Agitation/aggression and psychosis associated with dementia, severe or refractory; Bipolar disorder (treatment resistant); Psychosis in Parkinson disease

Medication Safety Issues
Sound-alike/look-alike issues:

CloZAPine may be confused with clonazePAM, cloNIDine, KlonoPIN

Clozaril may be confused with Clinoril, Colazal

Older Adult: High-Risk Medication:

Beers Criteria: Antipsychotics are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older due to an increased risk of stroke and a greater rate of cognitive decline and mortality in patients with dementia. Evidence also suggests there may be an increased risk of mortality with use independent of dementia. Avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. Use of antipsychotics may be appropriate for labeled indications including schizophrenia, bipolar disorder, Parkinson disease psychosis, adjunctive therapy in major depressive disorder, or for short-term use as an antiemetic (Beers Criteria [AGS 2023]).

Metabolism/Transport Effects

Substrate of CYP1A2 (Major), CYP2C19 (Minor), CYP2C9 (Minor), CYP2D6 (Minor), CYP3A4 (Major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Acetylcholinesterase Inhibitors: May decrease therapeutic effects of Agents with Clinically Relevant Anticholinergic Effects. Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Acetylcholinesterase Inhibitors. Risk C: Monitor

Aclidinium: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Acrivastine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Acrivastine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Adagrasib: May increase QTc-prolonging effects of CloZAPine. Adagrasib may increase serum concentration of CloZAPine. Management: Consider alternatives to this combination. If combined, monitor for increased clozapine toxicities, including QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider Therapy Modification

Adalimumab: May decrease serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers). Risk C: Monitor

Agents with Clinically Relevant Anticholinergic Effects: May increase constipating effects of CloZAPine. Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment. Risk D: Consider Therapy Modification

Agents With Seizure Threshold Lowering Potential: May increase adverse/toxic effects of CloZAPine. Specifically, the risk of seizures may be increased. Risk C: Monitor

Alcohol (Ethyl): CNS Depressants may increase CNS depressant effects of Alcohol (Ethyl). Risk C: Monitor

Aldesleukin: May increase serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor

Alfuzosin: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Alizapride: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Alpha-/Beta-Agonists: CloZAPine may decrease therapeutic effects of Alpha-/Beta-Agonists. Risk C: Monitor

Amifampridine: Agents With Seizure Threshold Lowering Potential may increase neuroexcitatory and/or seizure-potentiating effects of Amifampridine. Risk C: Monitor

Amifostine: Blood Pressure Lowering Agents may increase hypotensive effects of Amifostine. Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine. Risk D: Consider Therapy Modification

Amiodarone: May increase QTc-prolonging effects of CloZAPine. Amiodarone may increase serum concentration of CloZAPine. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities. Risk D: Consider Therapy Modification

Amisulpride (Oral): Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Amisulpride (Oral). Specifically, the risk of seizures may be increased. Risk C: Monitor

Amisulpride (Oral): May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Amisulpride (Oral): May increase hypotensive effects of Hypotension-Associated Agents. Risk C: Monitor

Amisulpride (Oral): May increase QTc-prolonging effects of QT-prolonging Agents (Moderate Risk). Risk C: Monitor

Anti-Parkinson Agents (Dopamine Agonist): Antipsychotic Agents (Second Generation [Atypical]) may decrease therapeutic effects of Anti-Parkinson Agents (Dopamine Agonist). Management: Consider avoiding atypical antipsychotic use in patients with Parkinson disease. If an atypical antipsychotic is necessary, consider using clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin). Risk D: Consider Therapy Modification

Antidiabetic Agents: Hyperglycemia-Associated Agents may decrease therapeutic effects of Antidiabetic Agents. Risk C: Monitor

Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may increase hypotensive effects of Antipsychotic Agents (Second Generation [Atypical]). Risk C: Monitor

Arginine: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. Risk C: Monitor

ARIPiprazole: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of ARIPiprazole. Specifically, the risk of seizures may be increased. Risk C: Monitor

Articaine: May increase CNS depressant effects of CNS Depressants. Management: Consider reducing the dose of articaine if possible when used in patients who are also receiving CNS depressants. Monitor for excessive CNS depressant effects with any combined use. Risk D: Consider Therapy Modification

Asenapine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Asenapine. Specifically, the risk of seizures may be increased. Risk C: Monitor

Azelastine (Nasal): May increase CNS depressant effects of CNS Depressants. Risk X: Avoid

Azithromycin (Systemic): May increase QTc-prolonging effects of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

Barbiturates: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Benperidol: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Benperidol. Risk C: Monitor

Benperidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Benperidol. Specifically, the risk of seizures may be increased. Risk C: Monitor

Benperidol: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Benperidol: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Benzgalantamine-Galantamine: May increase neurotoxic (central) effects of Antipsychotic Agents. Risk C: Monitor

Benzodiazepines: May increase adverse/toxic effects of CloZAPine. Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine. Monitor for respiratory depression, hypotension, and other toxicities if these agents are combined. Risk D: Consider Therapy Modification

Bimekizumab: May decrease serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers). Risk C: Monitor

Blonanserin: CNS Depressants may increase CNS depressant effects of Blonanserin. Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin. Risk D: Consider Therapy Modification

Blood Pressure Lowering Agents: May increase hypotensive effects of Antipsychotic Agents (Second Generation [Atypical]). Risk C: Monitor

Blood Pressure Lowering Agents: May increase hypotensive effects of Hypotension-Associated Agents. Risk C: Monitor

Botulinum Toxin-Containing Products: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Brexanolone: CNS Depressants may increase CNS depressant effects of Brexanolone. Risk C: Monitor

Brexpiprazole: CloZAPine may increase adverse/toxic effects of Brexpiprazole. Specifically, the risk of seizures may be increased. Brexpiprazole may decrease serum concentration of CloZAPine. Risk C: Monitor

Brimonidine (Topical): May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Brimonidine (Topical): May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Broccoli: May decrease serum concentration of CYP1A2 Substrates (High risk with Inducers). Risk C: Monitor

Bromopride: May increase adverse/toxic effects of Antipsychotic Agents. Risk X: Avoid

Bromperidol: May decrease hypotensive effects of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may increase hypotensive effects of Bromperidol. Risk X: Avoid

Bromperidol: May increase CNS depressant effects of CNS Depressants. Risk X: Avoid

Buprenorphine: CNS Depressants may increase CNS depressant effects of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants. Risk D: Consider Therapy Modification

BuPROPion: May increase neuroexcitatory and/or seizure-potentiating effects of Agents With Seizure Threshold Lowering Potential. Risk C: Monitor

BusPIRone: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Cabergoline: May decrease therapeutic effects of Antipsychotic Agents. Risk X: Avoid

Cannabinoid-Containing Products: Agents with Clinically Relevant Anticholinergic Effects may increase tachycardic effects of Cannabinoid-Containing Products. Risk C: Monitor

Cannabinoid-Containing Products: CNS Depressants may increase CNS depressant effects of Cannabinoid-Containing Products. Risk C: Monitor

Cannabis: May decrease serum concentration of CYP1A2 Substrates (High risk with Inducers). Risk C: Monitor

CarBAMazepine: May increase myelosuppressive effects of CloZAPine. More specifically, the risk of bone marrow suppression with this combination may be increased due to the independent myelosuppressive effects of the drugs. CarBAMazepine may decrease serum concentration of CloZAPine. Management: Avoid use with strong CYP3A4 inducers when possible. If combined, monitor patients closely and consider clozapine dose increases. Consider increased monitoring for neutropenia Risk D: Consider Therapy Modification

Cariprazine: May increase adverse/toxic effects of CloZAPine. Specifically, the risk of seizures may be increased. Cariprazine may decrease serum concentration of CloZAPine. Cariprazine may decrease active metabolite exposure of CloZAPine. Risk C: Monitor

Ceritinib: May increase QTc-prolonging effects of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

Cetirizine (Systemic): May increase CNS depressant effects of CNS Depressants. Management: Consider avoiding this combination if possible. If required, monitor for excessive sedation or CNS depression, limit the dose and duration of combination therapy, and consider CNS depressant dose reductions. Risk D: Consider Therapy Modification

Chloral Hydrate/Chloral Betaine: CNS Depressants may increase CNS depressant effects of Chloral Hydrate/Chloral Betaine. Management: Consider alternatives to the use of chloral hydrate or chloral betaine and additional CNS depressants. If combined, consider a dose reduction of either agent and monitor closely for enhanced CNS depressive effects. Risk D: Consider Therapy Modification

Chlormethiazole: May increase CNS depressant effects of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Risk D: Consider Therapy Modification

Chlorphenesin Carbamate: May increase adverse/toxic effects of CNS Depressants. Risk C: Monitor

Chlorprothixene: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Chlorprothixene. Risk C: Monitor

Cimetidine: May increase serum concentration of CloZAPine. Risk C: Monitor

Cimetropium: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Cimetropium. Risk X: Avoid

Ciprofloxacin (Systemic): May increase QTc-prolonging effects of CloZAPine. Ciprofloxacin (Systemic) may increase serum concentration of CloZAPine. Management: Reduce the clozapine dose to one-third of the original dose when adding ciprofloxacin and monitor closely for evidence of excessive QTc prolongation and clozapine toxicity. Resume the previous clozapine dose following ciprofloxacin discontinuation. Risk D: Consider Therapy Modification

Citalopram: CloZAPine may increase QTc-prolonging effects of Citalopram. CloZAPine may increase serotonergic effects of Citalopram. This could result in serotonin syndrome. Management: Monitor for QTc interval prolongation, ventricular arrhythmias, serotonin syndrome, and neuroleptic malignant syndrome when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

Clarithromycin: QT-prolonging Antipsychotics (Moderate Risk) may increase QTc-prolonging effects of Clarithromycin. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

Clofazimine: May increase serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor

Clothiapine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Clothiapine. Specifically, the risk of seizures may be increased. Risk C: Monitor

CNS Depressants: May increase adverse/toxic effects of CNS Depressants. Risk C: Monitor

COVID-19 Vaccines: May increase adverse/toxic effects of CloZAPine. COVID-19 Vaccines may increase serum concentration of CloZAPine. Risk C: Monitor

CYP1A2 Inducers (Moderate): May decrease serum concentration of CloZAPine. Risk C: Monitor

CYP1A2 Inducers (Weak): May decrease serum concentration of CloZAPine. Risk C: Monitor

CYP1A2 Inhibitors (Moderate): May increase serum concentration of CloZAPine. Risk C: Monitor

CYP1A2 Inhibitors (Strong): May increase serum concentration of CloZAPine. Management: Reduce the dose of clozapine to one-third of the original dose when adding a strong CYP1A2 inhibitor and monitor patient response closely. Return to the original clozapine dose when the strong CYP1A2 inhibitor is discontinued. Risk D: Consider Therapy Modification

CYP1A2 Inhibitors (Weak): May increase serum concentration of CloZAPine. Risk C: Monitor

CYP2D6 Inhibitors (Moderate): May increase serum concentration of CloZAPine. Risk C: Monitor

CYP2D6 Inhibitors (Strong): May increase serum concentration of CloZAPine. Risk C: Monitor

CYP3A4 Inducers (Moderate): May decrease serum concentration of CloZAPine. Risk C: Monitor

CYP3A4 Inducers (Strong): May decrease serum concentration of CloZAPine. Management: Avoid use with strong CYP3A4 inducers when possible. If combined, monitor patients closely and consider clozapine dose increases. Clozapine dose reduction and further monitoring may be required when strong CYP3A4 inducers are discontinued. Risk D: Consider Therapy Modification

CYP3A4 Inducers (Weak): May decrease serum concentration of CloZAPine. Risk C: Monitor

CYP3A4 Inhibitors (Moderate): May increase serum concentration of CloZAPine. Risk C: Monitor

CYP3A4 Inhibitors (Strong): May increase serum concentration of CloZAPine. Risk C: Monitor

Dabrafenib: May increase QTc-prolonging effects of CloZAPine. Dabrafenib may decrease serum concentration of CloZAPine. Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Additionally, monitor for decreased clozapine concentrations and efficacy. Risk C: Monitor

Dantrolene: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Daridorexant: May increase CNS depressant effects of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended. Risk D: Consider Therapy Modification

Deutetrabenazine: May increase adverse/toxic effects of Antipsychotic Agents. Specifically, the risk for akathisia, parkinsonism, or neuroleptic malignant syndrome may be increased. Risk C: Monitor

DexmedeTOMIDine: CNS Depressants may increase CNS depressant effects of DexmedeTOMIDine. Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression. Risk D: Consider Therapy Modification

Dexmethylphenidate-Methylphenidate: Antipsychotic Agents may increase adverse/toxic effects of Dexmethylphenidate-Methylphenidate. Dexmethylphenidate-Methylphenidate may increase adverse/toxic effects of Antipsychotic Agents. Specifically, the risk of extrapyramidal symptoms may be increased when these agents are combined. Risk C: Monitor

Diazoxide Choline: May increase serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Risk X: Avoid

Diazoxide: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Difelikefalin: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Difenoxin: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Dihydralazine: CNS Depressants may increase hypotensive effects of Dihydralazine. Risk C: Monitor

Dimethindene (Topical): May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Dinutuximab Beta: May increase serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor

Domperidone: QT-prolonging Agents (Moderate Risk) may increase QTc-prolonging effects of Domperidone. Risk X: Avoid

Donepezil: May increase neurotoxic (central) effects of Antipsychotic Agents. Risk C: Monitor

DroNABinol: Agents with Clinically Relevant Anticholinergic Effects may increase tachycardic effects of DroNABinol. Risk X: Avoid

DroPERidol: May increase CNS depressant effects of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Risk D: Consider Therapy Modification

DULoxetine: Blood Pressure Lowering Agents may increase hypotensive effects of DULoxetine. Risk C: Monitor

Elranatamab: May increase serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor

Eluxadoline: Agents with Clinically Relevant Anticholinergic Effects may increase constipating effects of Eluxadoline. Risk X: Avoid

Emedastine (Systemic): May increase CNS depressant effects of CNS Depressants. Management: Consider avoiding this combination if possible. If required, monitor for excessive sedation or CNS depression, limit the dose and duration of combination therapy, and consider CNS depressant dose reductions. Risk C: Monitor

Encorafenib: May increase QTc-prolonging effects of CloZAPine. Encorafenib may decrease serum concentration of CloZAPine. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation, ventricular arrhythmias, and decreased clozapine concentrations. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider Therapy Modification

Entacapone: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Epcoritamab: May increase serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor

Escitalopram: CloZAPine may increase serotonergic effects of Escitalopram. This could result in serotonin syndrome. CloZAPine may increase QTc-prolonging effects of Escitalopram. Management: Monitor for QTc interval prolongation, ventricular arrhythmias, serotonin syndrome, and neuroleptic malignant syndrome when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

Esketamine (Nasal): May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Fexinidazole: May increase QTc-prolonging effects of CloZAPine. Fexinidazole may decrease serum concentration of CloZAPine. Fexinidazole may increase serum concentration of CloZAPine. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Monitor for both increased and decreased clozapine serum concentrations and effects. Risk C: Monitor

Filgotinib: CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inducers) may decrease serum concentration of Filgotinib. Risk C: Monitor

Filgotinib: May increase serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor

Flunarizine: CNS Depressants may increase CNS depressant effects of Flunarizine. Risk X: Avoid

Flunitrazepam: CNS Depressants may increase CNS depressant effects of Flunitrazepam. Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available. Risk D: Consider Therapy Modification

Fluorouracil Products: CloZAPine may increase QTc-prolonging effects of Fluorouracil Products. Fluorouracil Products may increase myelosuppressive effects of CloZAPine. Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

Flupentixol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Flupentixol. Specifically, the risk of seizures may be increased. Risk C: Monitor

Foscarbidopa: May decrease serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inducers). Risk C: Monitor

Fusidic Acid (Systemic): May increase serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Consider avoiding this combination if possible. If required, monitor patients closely for increased adverse effects of the CYP3A4 substrate. Risk D: Consider Therapy Modification

Gastrointestinal Agents (Prokinetic): Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Gastrointestinal Agents (Prokinetic). Risk C: Monitor

Gepotidacin: May decrease anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Glofitamab: May increase serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor

Glucagon: Agents with Clinically Relevant Anticholinergic Effects may increase adverse/toxic effects of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. Risk C: Monitor

Glycopyrrolate (Oral Inhalation): Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Glycopyrrolate (Oral Inhalation). Risk X: Avoid

Glycopyrronium (Topical): May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Guanethidine: Antipsychotic Agents may decrease therapeutic effects of Guanethidine. Risk C: Monitor

Haloperidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Haloperidol. Specifically, the risk of seizures may be increased. Risk C: Monitor

Haloperidol: QT-prolonging Antipsychotics (Moderate Risk) may increase QTc-prolonging effects of Haloperidol. Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk. Risk C: Monitor

Herbal Products with Blood Pressure Lowering Effects: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Huperzine A: May increase neurotoxic (central) effects of Antipsychotic Agents. Risk C: Monitor

HydrOXYzine: May increase CNS depressant effects of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant. Risk D: Consider Therapy Modification

Hypotension-Associated Agents: Blood Pressure Lowering Agents may increase hypotensive effects of Hypotension-Associated Agents. Risk C: Monitor

Iloperidone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Iloperidone. Specifically, the risk of seizures may be increased. Risk C: Monitor

Iloperidone: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Interleukin-6 (IL-6) Inhibiting Therapies: May decrease serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers). Risk C: Monitor

Iohexol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs. Risk D: Consider Therapy Modification

Iomeprol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs. Risk D: Consider Therapy Modification

Iopamidol: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs. Risk D: Consider Therapy Modification

Ipratropium (Nasal): May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Ipratropium (Oral Inhalation): May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Itopride: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Itopride. Risk C: Monitor

Ixabepilone: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Kava Kava: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Ketotifen (Systemic): May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Kratom: May increase CNS depressant effects of CNS Depressants. Risk X: Avoid

Lemborexant: May increase CNS depressant effects of CloZAPine. Lemborexant may increase serum concentration of CloZAPine. Management: Dosage adjustments of lemborexant and clozapine may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary. Consider monitoring clozapine concentrations. Risk D: Consider Therapy Modification

Leniolisib: May increase serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk X: Avoid

Levocetirizine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Levoketoconazole: QT-prolonging Agents (Moderate Risk) may increase QTc-prolonging effects of Levoketoconazole. Risk X: Avoid

Levosulpiride: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Levosulpiride. Risk X: Avoid

Lithium: May increase neurotoxic effects of Antipsychotic Agents. Lithium may decrease serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine. Risk C: Monitor

Lofexidine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Lonafarnib: May increase QTc-prolonging effects of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

Loxapine: CNS Depressants may increase CNS depressant effects of Loxapine. Management: Consider reducing the dose of CNS depressants administered concomitantly with loxapine due to an increased risk of respiratory depression, sedation, hypotension, and syncope. Risk D: Consider Therapy Modification

Lumateperone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Lumateperone. Specifically, the risk of seizures may be increased. Risk C: Monitor

Lurasidone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Lurasidone. Specifically, the risk of seizures may be increased. Risk C: Monitor

Magnesium Sulfate: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Melperone: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Metergoline: May decrease antihypertensive effects of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may increase orthostatic hypotensive effects of Metergoline. Risk C: Monitor

Metergoline: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Methotrimeprazine: CNS Depressants may increase CNS depressant effects of Methotrimeprazine. Methotrimeprazine may increase CNS depressant effects of CNS Depressants. Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression. Risk D: Consider Therapy Modification

Methoxyflurane: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Metoclopramide: May increase adverse/toxic effects of Antipsychotic Agents. Risk X: Avoid

MetyroSINE: CNS Depressants may increase sedative effects of MetyroSINE. Risk C: Monitor

MetyroSINE: May increase adverse/toxic effects of Antipsychotic Agents. Specifically, the risk for extrapyramidal symptoms and excessive sedation may be increased. Risk C: Monitor

Minocycline (Systemic): May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Mirabegron: Agents with Clinically Relevant Anticholinergic Effects may increase adverse/toxic effects of Mirabegron. Risk C: Monitor

Mirikizumab: May decrease serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers). Risk C: Monitor

Molindone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Molindone. Specifically, the risk of seizures may be increased. Risk C: Monitor

Molsidomine: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Mosunetuzumab: May increase serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor

Moxonidine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Myelosuppressive Agents: May increase adverse/toxic effects of CloZAPine. Specifically, the risk for neutropenia may be increased. Risk C: Monitor

Nabilone: May increase CNS depressant effects of CNS Depressants. Risk X: Avoid

Naftopidil: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Nalfurafine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Nemolizumab: May decrease serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers). Risk C: Monitor

Nicergoline: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Nicorandil: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Nitroglycerin: Agents with Clinically Relevant Anticholinergic Effects may decrease absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. Risk C: Monitor

Nitroprusside: Blood Pressure Lowering Agents may increase hypotensive effects of Nitroprusside. Risk C: Monitor

Noscapine: CNS Depressants may increase adverse/toxic effects of Noscapine. Risk X: Avoid

Obinutuzumab: May increase hypotensive effects of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion. Risk D: Consider Therapy Modification

Olopatadine (Nasal): May increase CNS depressant effects of CNS Depressants. Risk X: Avoid

Omeprazole: May decrease serum concentration of CloZAPine. Omeprazole may increase serum concentration of CloZAPine. Risk C: Monitor

Ondansetron: May increase QTc-prolonging effects of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation, ventricular arrhythmias, including torsades de pointes, when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

Opicapone: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Opioid Agonists: CNS Depressants may increase CNS depressant effects of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider Therapy Modification

Orphenadrine: CNS Depressants may increase CNS depressant effects of Orphenadrine. Risk X: Avoid

Oxatomide: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Oxomemazine: May increase CNS depressant effects of CNS Depressants. Risk X: Avoid

Oxybate Salt Products: CNS Depressants may increase CNS depressant effects of Oxybate Salt Products. Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use Risk D: Consider Therapy Modification

OxyCODONE: CNS Depressants may increase CNS depressant effects of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider Therapy Modification

Pacritinib: May increase serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor

Paliperidone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Paliperidone. Specifically, the risk of seizures may be increased. Risk C: Monitor

Paliperidone: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Paraldehyde: CNS Depressants may increase CNS depressant effects of Paraldehyde. Risk X: Avoid

Pentamidine (Systemic): May increase QTc-prolonging effects of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

Pentoxifylline: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Perampanel: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Perazine: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk C: Monitor

Periciazine: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Periciazine. Specifically, the risk of seizures may be increased. Risk C: Monitor

Periciazine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Phenylephrine (Systemic): CloZAPine may decrease therapeutic effects of Phenylephrine (Systemic). Risk C: Monitor

Pholcodine: Blood Pressure Lowering Agents may increase hypotensive effects of Pholcodine. Risk C: Monitor

Phosphodiesterase 5 Inhibitors: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Pimozide: May increase QTc-prolonging effects of QT-prolonging Agents (Moderate Risk). Risk X: Avoid

Pipamperone: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Pipamperone. Specifically, the risk of seizures may be increased. Risk X: Avoid

Piperaquine: QT-prolonging Agents (Moderate Risk) may increase QTc-prolonging effects of Piperaquine. Risk X: Avoid

Pizotifen: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. Risk C: Monitor

Potassium Chloride: Agents with Clinically Relevant Anticholinergic Effects may increase ulcerogenic effects of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride. Risk X: Avoid

Potassium Citrate: Agents with Clinically Relevant Anticholinergic Effects may increase ulcerogenic effects of Potassium Citrate. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate. Risk X: Avoid

Pramlintide: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. These effects are specific to the GI tract. Risk X: Avoid

Primaquine: May increase serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Risk C: Monitor

Procarbazine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Propofol: QT-prolonging Antipsychotics (Moderate Risk) may increase QTc-prolonging effects of Propofol. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

Prostacyclin Analogues: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

QT-prolonging Agents (Highest Risk): May increase QTc-prolonging effects of CloZAPine. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities. Risk D: Consider Therapy Modification

QT-prolonging Antidepressants (Moderate Risk): May increase constipating effects of CloZAPine. CloZAPine may increase QTc-prolonging effects of QT-prolonging Antidepressants (Moderate Risk). Management: Consider alternatives to this combination whenever possible. If combined, consider prophylactic laxatives and monitor closely for signs and symptoms of gastrointestinal hypomotility, QTc prolongation, and serotonin syndrome. Risk D: Consider Therapy Modification

QT-prolonging Antipsychotics (Moderate Risk): May increase QTc-prolonging effects of CloZAPine. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

QT-prolonging Class IC Antiarrhythmics (Moderate Risk): May increase QTc-prolonging effects of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

QT-Prolonging Inhalational Anesthetics (Moderate Risk): May increase QTc-prolonging effects of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

QT-prolonging Kinase Inhibitors (Moderate Risk): CloZAPine may increase QTc-prolonging effects of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

QT-prolonging Miscellaneous Agents (Moderate Risk): May increase QTc-prolonging effects of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May increase QTc-prolonging effects of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

QT-prolonging Quinolone Antibiotics (Moderate Risk): May increase QTc-prolonging effects of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

Quinagolide: Antipsychotic Agents may decrease therapeutic effects of Quinagolide. Risk C: Monitor

Quinagolide: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

QuiNIDine: CloZAPine may increase QTc-prolonging effects of QuiNIDine. CloZAPine may increase anticholinergic effects of QuiNIDine. QuiNIDine may increase serum concentration of CloZAPine. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider Therapy Modification

Ramosetron: Agents with Clinically Relevant Anticholinergic Effects may increase constipating effects of Ramosetron. Risk C: Monitor

Revefenacin: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Revefenacin. Risk X: Avoid

Rilmenidine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

RisperiDONE: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of RisperiDONE. Specifically, the risk of seizures may be increased. Risk C: Monitor

Ritlecitinib: May increase serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor

Rivastigmine: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Rivastigmine. Rivastigmine may decrease therapeutic effects of Agents with Clinically Relevant Anticholinergic Effects. Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects. Risk D: Consider Therapy Modification

Ropeginterferon Alfa-2b: CNS Depressants may increase adverse/toxic effects of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania). Risk D: Consider Therapy Modification

Saquinavir: May increase QTc-prolonging effects of CloZAPine. Risk X: Avoid

Secretin: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin. Risk D: Consider Therapy Modification

Serotonergic Agents (High Risk): May increase adverse/toxic effects of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Risk C: Monitor

Sertindole: May increase QTc-prolonging effects of QT-prolonging Agents (Moderate Risk). Risk X: Avoid

Silodosin: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may increase adverse/toxic effects of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. Risk C: Monitor

Sofpironium: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Sofpironium. Risk X: Avoid

Sulpiride: Antipsychotic Agents may increase adverse/toxic effects of Sulpiride. Risk X: Avoid

Suvorexant: CNS Depressants may increase CNS depressant effects of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Risk D: Consider Therapy Modification

Talquetamab: May increase serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor

Tarlatamab: May increase serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor

Taurursodiol: May decrease serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inducers). Risk X: Avoid

Tetrabenazine: May increase adverse/toxic effects of Antipsychotic Agents. Specifically, the risk for NMS and extrapyramidal symptoms may be increased. Risk C: Monitor

Thalidomide: CNS Depressants may increase CNS depressant effects of Thalidomide. Risk X: Avoid

Thiazide and Thiazide-Like Diuretics: Agents with Clinically Relevant Anticholinergic Effects may increase serum concentration of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Thioridazine: QT-prolonging Agents (Moderate Risk) may increase QTc-prolonging effects of Thioridazine. Risk X: Avoid

Tiapride: Agents with Clinically Relevant Anticholinergic Effects may decrease therapeutic effects of Tiapride. Risk C: Monitor

Tiotropium: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Tiotropium. Risk X: Avoid

Tobacco (Smoked): May decrease serum concentration of CloZAPine. Risk C: Monitor

Topiramate: Agents with Clinically Relevant Anticholinergic Effects may increase adverse/toxic effects of Topiramate. Risk C: Monitor

Trimethobenzamide: Agents with Clinically Relevant Anticholinergic Effects may increase anticholinergic effects of Trimethobenzamide. Risk C: Monitor

Umeclidinium: May increase anticholinergic effects of Agents with Clinically Relevant Anticholinergic Effects. Risk X: Avoid

Ustekinumab: May decrease serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers). Risk C: Monitor

Valerian: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Valproic Acid and Derivatives: May increase adverse/toxic effects of CloZAPine. Specifically, the risk for myocarditis, neutropenia, or CNS toxicities may be increased. Valproic Acid and Derivatives may increase serum concentration of CloZAPine. Valproic Acid and Derivatives may decrease serum concentration of CloZAPine. Valproic Acid and Derivatives may decrease active metabolite exposure of CloZAPine. Risk C: Monitor

Vasopressin: Drugs Suspected of Causing Diabetes Insipidus may decrease therapeutic effects of Vasopressin. Specifically, the pressor and antidiuretic hormone effects of vasopressin may be decreased. Risk C: Monitor

Vedolizumab: May decrease serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers). Risk C: Monitor

Voriconazole: May increase QTc-prolonging effects of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

Zolpidem: CNS Depressants may increase CNS depressant effects of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Risk D: Consider Therapy Modification

Zuranolone: May increase CNS depressant effects of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects. Risk D: Consider Therapy Modification

Reproductive Considerations

Evaluate pregnancy status and provide preconception counseling prior to initiating treatment in patients who could become pregnant (APA [Keepers 2020]; BAP [McAllister-Williams 2017]; CANMAT [Yatham 2018]).

Hormonal contraceptives may increase the serum concentration of clozapine during the active hormonal phase compared to the inactive non-hormonal phase. Dose adjustments of clozapine may be needed; monitor closely. Alternative contraception methods that do not undergo first-pass hepatic metabolism may be preferred (McCloskey 2021). Consult drug interactions database for detailed information specific to the use of clozapine and contraceptives.

Patients effectively treated may continue their current antipsychotic medication when planning a pregnancy unless contraindications exist (ACOG 2023; BAP [McAllister-Williams 2017]); the lowest effective dose and avoidance of polytherapy is recommended (BAP [Barnes 2020]; BAP [McAllister-Williams 2017]; CANMAT [Yatham 2018]). Management of mental health conditions in patients who could become pregnant should be based on a shared decision-making process that considers the possibility of pregnancy during treatment and the risks of discontinuing antipsychotic therapy (ACOG 2023; BAP [McAllister-Williams 2017]; CANMAT [Yatham 2018]).

Antipsychotic agents may be associated with sexual dysfunction. Some second generation (atypical) antipsychotics may cause hyperprolactinemia, resulting in menstrual disorders or impaired spermatogenesis. Consider changing to a medication that is prolactin-sparing in patients with clinical symptoms. Contraception should be provided if pregnancy is not desired, as unintended pregnancies may occur when changing to a prolactin-sparing medication (APA [Keepers 2020]; BAP [McAllister-Williams 2017]).

Pregnancy Considerations

Clozapine and the desmethyl metabolite (norclozapine) cross the placenta and can be detected in the fetal blood and amniotic fluid (Barnas 1994; Imaz 2018).

Outcome data following exposure to second generation (atypical) antipsychotics (SGAs) as a class do not show a significant increased risk of major congenital malformations (BAP [Barnes 2020]); however, specific outcomes vary due to differences in study design (BAP [McAllister-Williams 2017]; Beex-Oosterhuis 2021; Damkier 2018; Ellfolk 2021; Huybrechts 2016; Huybrechts 2023; Liu 2023; Mehta 2017; Terrana 2015; Thanigaivel 2022; Viguera 2021; Wang 2021). Clozapine is one of the SGAs with more limited data for first-trimester exposure (BAP [McAllister-Williams 2017]). Additional studies are needed for individual agents and specific outcomes (BAP [Barnes 2020]). Data related to the long-term effects of in utero antipsychotic exposure on infant neurodevelopment and behavior are limited (BAP [McAllister-Williams 2017]; Straub 2022; Swetlik 2024).

Antipsychotic use during the third trimester of pregnancy increases the risk for extrapyramidal symptoms and/or withdrawal symptoms in newborns following delivery (Viguera 2023). Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor. Monitor infants and manage appropriately. These effects may require prolonged hospitalization or resolve within hours or days without specific treatment. Tapering the dose late in pregnancy to reduce the risk of symptoms is not recommended (APA [Keepers 2020]).

Atypical antipsychotics are associated with metabolic changes and the risk varies by specific agent. Available studies that evaluated the risk of developing gestational diabetes mellitus (GDM) during antipsychotic therapy have conflicting results, possibly due to differences in study design (ACOG 2023; Uguz 2019). High-risk metabolic SGAs include clozapine, which is associated with higher risk for GDM and infants born large for GA than those that are non-exposed (Heinonen 2022). Pregnant patients with diabetes mellitus or GDM may continue antipsychotic treatment (ACOG 2023). Consider the metabolic risks of the specific antipsychotic if treatment is initiated for the first time during pregnancy (Heinonen 2022). Screening for GDM should continue as part of standard prenatal care; early screening is not needed due to psychiatric medication exposure (ACOG 2023; BAP [McAllister-Williams 2017]).

Untreated and undertreated mental health conditions are associated with adverse pregnancy outcomes (ACOG 2023). Adverse obstetric and neonatal outcomes are associated with schizophrenia; however, comparisons between treated and untreated pregnancies are limited (BAP [McAllister-Williams 2017]). Untreated bipolar disorder is associated with fetal growth restriction, preterm birth, adverse neurodevelopment, and may increase the risk of postpartum psychosis, worsening mood, and postpartum hospitalization. Discontinuing effective medications during pregnancy increases the risk of symptom relapse (ACOG 2023). Patients effectively treated for schizophrenia or bipolar disorder pre-pregnancy may use the same medication during pregnancy unless contraindications exist (ACOG 2023; APA [Keepers 2020]). SGAs are better tolerated than first-generation (typical) antipsychotics (ACOG 2023).

Management of mental health conditions should be made as part of a shared decision-making process (ACOG 2023; BAP [McAllister-Williams 2017]). Treatment should not be withheld or discontinued based only on pregnancy status. When medications are used, the lowest effective dose of a single agent is recommended. Optimize dosing prior to changing a medication or adding additional agents whenever possible. Close monitoring for symptom improvement with a validated screening tool during pregnancy is recommended. Manage side effects as needed (ACOG 2023).

Data collection to monitor pregnancy and infant outcomes following exposure to psychiatric medications is ongoing. Encourage pregnant patients 45 years of age and younger with a history of psychiatric illness to enroll in the National Pregnancy Registry for Psychiatric Mediations (1-866-961-2388 or https://womensmentalhealth.org/research/pregnancyregistry/).

Breastfeeding Considerations

Clozapine is present in breast milk.

Data related to the presence of clozapine in breast milk are limited:

- Clozapine breast milk concentrations were higher than the maternal plasma in 1 case report. Breast milk was sampled in a patient following use of clozapine 50 mg/day during pregnancy. On the first day postpartum, maternal plasma and breast milk concentrations were 14.7 ng/mL and 63.5 ng/mL, respectively. Three days after delivery the dose was increased to 100 mg/day. Concentrations of clozapine in the maternal plasma were 41.4 ng/mL and 114.6 ng/mL in breast milk 1 week after delivery. The infant was not breastfed (Barnas 1994).

Infant outcome data following exposure to clozapine via breast milk are also limited (Imaz 2018; Mendhekar 2007; Uguz 2020; Uygur 2019). A review article provides information on 4 infants exposed to clozapine via breast milk. Two had no adverse events, excessive sleepiness was reported in 1, and agranulocytosis which resolved when breastfeeding was discontinued occurred in 1 infant. No additional details were provided (Dev 1995). Drowsiness, irritability, motor abnormalities, poor feeding, sedation, and slowed development have been reported in infants exposed to antipsychotics via breast milk. Monitor breastfed infants, especially those who are premature or of low birth weight, or when other sedative drugs are also prescribed (BAP [Barnes]; BAP [McAllister-Williams 2017]).

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother; monitor breastfed infants for excess sedation and neutropenia. Due to the potential for adverse effects to an infant exposed via breast milk (eg, blood dyscrasias, neonatal seizures), use of clozapine is not recommended in patients who are breastfeeding (BAP [Barnes 2020]; BAP [McAllister-Williams 2017]).

Dietary Considerations

Some products may contain phenylalanine.

Monitoring Parameters

The only mandatory monitoring is the routine ANC, however, monitoring of several other clinical outcomes is recommended. Clozapine-treated patients should be monitored as frequently as possible in the first few weeks during titration.

Frequency of Antipsychotic Monitoring for Clozapine a,b

Monitoring parameter

Frequency of monitoring

Comments

a For all monitoring parameters, it is appropriate to check at baseline and when clinically relevant (based on symptoms or suspected adverse reactions) in addition to the timeline.

b ADA 2004, APA [Keepers 2020], De Hert 2011a, De Hert 2011b, Gugger 2011, Knoph 2018; Nielsen 2012, Palmer 2008, manufacturer's labeling.

c Signs and symptoms of myocarditis include asymptomatic tachycardia, chest pain, eosinophilia, fatigue, fever, palpitations, peripheral edema, and shortness of breath.

d Risk factors for extrapyramidal symptoms (EPS) include prior history of EPS, high doses of antipsychotics, young age (children and adolescents at higher risk than adults), and dopaminergic affinity of individual antipsychotic.

e Risk factors for tardive dyskinesia include age >55 years; females; White or African ethnicity; presence of a mood disorder, intellectual disability, or central nervous system injury; and past or current EPS.

Adherence

Every visit

Blood chemistries (electrolytes, renal function, liver function, thyroid stimulating hormone)

Annually

Bowel function

Every visit

CBC (ANC)

Refer to “ANC monitoring” section following this table (~weekly for 6 months, biweekly for 6 months, then monthly after 1 year).

ECG

Check at baseline to monitor for myocarditis only if there are cardiac risk factors; repeat if significant change in dose or addition of other QTc-prolonging drugs in patients with risk factors or elevated baseline QTc.

Echocardiogram

Check at baseline only if there are cardiac risk factors; repeat if signs or symptoms of myocarditis develop.c

To monitor for myocarditis

Extrapyramidal symptoms

Every visit; 4 weeks after initiation and dose change; annually. Use a formalized rating scale at least annually or every 6 months if high risk.d

Fall risk

Every visit

Fasting plasma glucose/HbA1c

4 months after initiation; annually

Check more frequently than annually if abnormal. Follow diabetes guidelines.

Lipid panel

4 months after initiation; annually

Check more frequently than annually if abnormal. Follow lipid guidelines.

Mental status and alertness

Every visit

Metabolic syndrome history

Annually

Evaluate for personal and family history of obesity, diabetes, dyslipidemia, hypertension, or cardiovascular disease.

Myocarditis monitoring (C-reactive protein, eosinophils, troponin)

Repeat weekly during first 6 weeks of treatment OR if signs or symptoms of myocarditis develop.c

Prolactin

Ask about symptoms at every visit until dose is stable. Check prolactin level if symptoms are reported.

Hyperprolactinemia symptoms: Changes in menstruation, libido, gynecomastia, development of galactorrhea, and erectile and ejaculatory function.

Serum clozapine concentration

As clinically appropriate.

Check concentrations when trying to establish maintenance dose or to confirm adherence.

Smoking patterns

Regularly; assess with hospitalization.

Cessation may cause toxicity in a patient stabilized on clozapine. In patients expected to have a prolonged hospital stay with forced smoking cessation, consider baseline serum clozapine levels and/or empiric dosage adjustments.

Tardive dyskinesia

Every visit; annually. Use a formalized rating scale at least annually or every 6 months if high risk.e

Vital signs (BP, orthostatics, temperature, pulse, signs of infection)

Every visit (at least weekly during first 3 to 4 weeks of treatment); 4 weeks after dose change. May stop monitoring temperature after first 8 weeks of treatment.

Weight/height/BMI

8 and 12 weeks after initiation and dose change; quarterly.

Consider monitoring waist circumference at baseline and annually, especially in patients with or at risk for metabolic syndrome. Consider changing antipsychotic if BMI increases by ≥1 unit. Some experts recommend checking weight and height at every visit.

ANC monitoring:

US labeling:

Note: See below for considerations during COVID-19 quarantine, in patients with Duffy-null associated neutrophil counts (previously called benign ethnic neutropenia), hospice situations, use of concurrent medications that cause neutropenia, and Canadian labeling. Laboratory hematology results may be presented in different units; 1 mcL = 1 mm3.

General population: Prior to initiating treatment, obtain a baseline ANC; the ANC must be ≥1,500/mm3 for the general population in order to initiate treatment. During the first 6 months of treatment, monitor the ANC weekly. If the ANC remains ≥1,500/mm3, the monitoring frequency can be reduced to every 2 weeks for the next 6 months. If the ANC remains ≥1,500/mm3 for the second 6 months of continuous therapy, the ANC monitoring frequency can be reduced to once every 4 weeks.

Treatment interruption: If ANC is ≥1,500/mm3 and treatment is interrupted for <30 days, continue monitoring as before; if ≥30 days, monitor as if a new patient.

Treatment discontinuation: For abrupt clozapine discontinuation for a reason unrelated to neutropenia in the general population, continuation of ANC monitoring is recommended until the ANC is ≥1,500/mm3. Additional ANC monitoring is required for any patient reporting onset of fever, defined as a temperature of ≥38.5°C (≥101.3°F), during the 2 weeks after discontinuation.

Monitor patients for psychosis and cholinergic rebound (eg, headache, nausea, vomiting, diarrhea, profuse diaphoresis).

Hematologic toxicity monitoring: Confirm all initial reports of ANC <1,500/mm3 with a repeat ANC within 24 hours.

Fever: Interrupt clozapine as a precautionary measure in any patient who develops a fever, defined as a temperature of ≥38.5°C (≥101.3°F), and obtain an ANC level. Fever is often the first sign of neutropenic infection, however, it is also a symptom of Duffy-null associated neutrophil.

Mild neutropenia (1,000 to 1,499/mm3): Continue treatment; monitor ANC 3 times weekly until ≥1,500/mm3 and then return to previous monitoring schedule.

Moderate neutropenia (500 to 999/mm3): Interrupt therapy, recommend hematology consultation, and begin daily ANC monitoring until ANC ≥1,000/mm3 and then may consider restarting therapy. Follow with 3 times weekly monitoring until ANC ≥1,500/mm3. Once ANC ≥1,500/mm3, check ANC weekly for 4 weeks and then return to previous monitoring schedule.

If fever occurs in any patient with an ANC <1,000/mm3, initiate appropriate workup and treatment for infection.

Severe neutropenia (<500/mm3): Interrupt therapy, recommend hematology consultation, and begin daily ANC monitoring until ANC ≥1,000/mm3. Follow with 3 times weekly monitoring until ANC ≥1,500/mm3. Do not rechallenge unless prescriber determines benefits outweigh risks. If rechallenged, resume treatment as a new patient once ANC ≥1,500/mm3.

Duffy-null associated neutrophil count (formerly called benign ethnic neutropenia): Prior to initiating treatment, obtain at least 2 baseline ANC levels, including the ANC; the ANC must be ≥1,000/mm3 for patients with documented Duffy-null associated neutrophil count in order to initiate treatment. During the first 6 months of treatment, monitor the ANC weekly. If the ANC remains ≥1,000/mm3, the monitoring frequency can be reduced to every 2 weeks for the next 6 months. If the ANC remains ≥1,000/mm3 for the second 6 months of continuous therapy, the ANC monitoring frequency can be reduced to once every 4 weeks.

Treatment interruption: If ANC is ≥1,000/mm3 and treatment is interrupted for <30 days, continue monitoring as before; if ≥30 days, monitor as if a new patient.

Treatment discontinuation: For abrupt clozapine discontinuation for a reason unrelated to neutropenia in patients with Duffy-null associated neutrophil, continuation of ANC monitoring is recommended until the ANC is ≥1,000/mm3 or above the baseline. Additional ANC monitoring is required for any patient reporting onset of fever, defined as a temperature of ≥38.5°C (≥101.3°F), during the 2 weeks after discontinuation.

Monitor patients for psychosis and cholinergic rebound (eg, headache, nausea, vomiting, diarrhea, profuse diaphoresis).

Hematologic toxicity monitoring: Confirm all initial reports of ANC <1,500/mm3 with a repeat ANC within 24 hours.

Fever: Interrupt clozapine as a precautionary measure in any patient who develops a fever, defined as a temperature of ≥38.5°C (≥101.3°F), and obtain an ANC level. Fever is often the first sign of neutropenic infection, however, it is also a symptom of Duffy-null associated neutrophil count.

Duffy-null associated neutrophil count (500 to 999/mm3): Continue therapy, recommend hematology consultation, and begin 3 times weekly ANC monitoring until ANC ≥1,000/mm3 or greater than or equal to patient's known baseline. Once ANC ≥1,000/mm3 or patient's known baseline, check ANC weekly for 4 weeks and then return to previous monitoring schedule.

If fever occurs in any patient with an ANC <1,000/mm3, initiate appropriate workup and treatment for infection.

Severe Duffy-null associated neutrophil (<500/mm3): Interrupt therapy, recommend hematology consultation, and begin daily ANC monitoring until ANC ≥500/mm3. Follow with 3 times weekly monitoring until ANC greater than or equal to patient's baseline. Do not rechallenge unless prescriber determines benefits outweigh risks. If rechallenged, resume treatment as a new patient once ANC ≥1,000/mm3.

COVID-19 considerations: Due to challenges with self-isolation or quarantine, the FDA recommends considering whether or not there are compelling reasons to complete required laboratory testing and to weigh the benefits and risks of continuing treatment in the absence of laboratory testing (FDA 2020).

A meta-analysis of 7 studies suggests the risk for neutropenia peaks within the first month of therapy and drops over time to negligible levels by 1 year of treatment (Myles 2018). Some experts suggest it may be reasonable to reduce testing frequency to every 3 months in patients who have received clozapine for ≥1 year and have never had an ANC <2,000/mm3 (or <1,500/mm3 if history of Duffy-null associated neutrophil count [formerly called benign ethnic neutropenia]). Patients without ANC monitoring who develop symptoms such as sore throat and fever should be assessed for neutropenia and COVID-19. Expert consensus guidelines suggest the following modifications for consideration (Chengappa 2022; Siskind 2020b):

ANC monitoring:

Continuous clozapine treatment for 1 year: If there is no safe or practical access to lab draws, may reduce frequency of ANC testing to every 3 months and dispense a 90-day supply if patient has never had an ANC <2,000/mm3 (or <1,500/mm3 if history of Duffy-null associated neutrophil count [formerly called benign ethnic neutropenia]).

Continuous clozapine treatment for 6 to 12 months: Make decisions about ANC monitoring on a case by case basis.

Initiating clozapine: Adhere to standard protocols for ANC monitoring for the first 6 months.

Infection symptoms:

Patients without ANC monitoring who develop symptoms such as sore throat and fever should be assessed for neutropenia and COVID-19 (Chengappa 2022; Siskind 2020b). Considerations with COVID-19 and other infections include:

• In patients with any symptoms of infection such as cough, fever and chills, sore throat, or other flu-like symptoms, complete an urgent physician assessment including an ANC. Clozapine may be associated with a higher risk of pneumonia due to sialorrhea and aspiration.

• Clozapine levels may increase with acute systemic infections and lead to symptoms of acute clozapine toxicity including sedation, myoclonus, and seizures. In addition, patients with respiratory infections may reduce or cease smoking, also leading to increased clozapine levels. If patients with fever and flu-like symptoms develop symptoms of clozapine toxicity, consider reducing the clozapine dose by up to 50%. Continue the lower dose until 3 days after the fever has subsided, then increase slowly to the pre-fever dose. Use clozapine serum levels as needed to assist with dosing adjustments, particularly after large dose changes, inadequate response, or unexpected adverse effects (Siskind 2020b).

Hospice patients: For hospice patients (ie, terminally ill patients with an estimated life expectancy of ≤6 months), ANC monitoring may be reduced to a frequency of once every 6 months after a discussion with the patient and caregiver. Base ANC monitoring on individual treatment needs to control psychiatric symptoms and terminal illness.

Concurrent use of other drugs associated with neutropenia: If clozapine is used concurrently with an agent known to cause neutropenia (eg, some chemotherapeutic agents), consider monitoring patients more closely. Consult with treating oncologist in patients receiving concomitant chemotherapy.

Canadian labeling:

Prior to initiating treatment, obtain a baseline ANC; the ANC must be ≥2,000/mm3 in order to initiate treatment. Initiate treatment in an inpatient setting or an outpatient setting with medical supervision and monitor of vital signs for at least 6 to 8 hours after the first few doses. During the first 6 months (26 weeks) of treatment, ANC should be obtained at baseline and at least weekly. If count remains acceptable (ANC ≥2,000/mm3) during this time period, then may be monitored every other week for the next 6 months (26 weeks). If ANC continues to remain within these acceptable limits after the second 6 months (26 weeks) of therapy, monitoring can be decreased to every 4 weeks.

Special populations: Patients with low WBC counts because of Duffy-null associated neutrophil count (formerly called benign ethnic neutropenia) should be given special consideration and may be started on clozapine after consultation with a hematologist. Patients with a history of bone marrow disorders should be evaluated by a hematologist prior to starting clozapine; therapy may be initiated if the benefit outweighs the risk.

Treatment interruption: Note: Only applies to patients with ANC ≥2,000/mm3. If treatment is interrupted for <3 days, continue monitoring as before. If ≥3 days of therapy interruption, resume weekly hematologic monitoring for an additional 6 weeks, then resume previous monitoring schedule. If treatment is interrupted for >4 weeks, monitor as if a new patient.

Hematologic toxicity monitoring:

ANC 1,500 to 2,000/mm3: Continue treatment; monitor ANC twice weekly until counts stabilize or increase, then return to previous monitoring schedule.

ANC <1,500/mm3: Discontinue treatment and do not rechallenge patient; continue to monitor WBC/ANC daily until hematologic abnormality is resolved; monitor for signs of infection. If WBC falls <1,000/mm3 or ANC falls <500/mm3, place patient in protective isolation with close observation.

Eosinophilia (eosinophil count >3,000/mm3): Discontinue treatment and restart only after the eosinophil count is <1,000/mm3. Patients with both eosinophilia and clozapine-induced myocarditis should not be re-exposed to clozapine.

Thrombocytopenia (platelet count <50,000/mm3): Discontinue treatment.

Reference Range

Timing of serum samples: Draw trough ~10 hours (range: 8 to 12 hours) after last dose; typically immediately before morning dose (Gaertner 2001b; Hiemke 2018; VanderZwaag 1996).

Therapeutic reference range (clozapine only): 350 to 600 ng/mL (SI: 1,071 to 1,836 nmol/L). Ratios of clozapine to the metabolite norclozapine may provide perspectives on the metabolism of clozapine. A clozapine:norclozapine ratio <2 suggests the involvement of factors that induce clozapine metabolism, including cigarette smoking and interacting medications. A ratio >2 suggests a nontrough sample, a recent missed dose, or metabolism inhibition or saturation (Costa-Dookhan 2020).

Laboratory alert level (clozapine): 1,000 ng/mL (SI: 3,060 nmol/L) (Hiemke 2018).

Mechanism of Action

The therapeutic efficacy of clozapine (dibenzodiazepine antipsychotic) is proposed to be mediated through antagonism of the dopamine type 2 (D2) and serotonin type 2A (5-HT2A) receptors. In addition, it acts as an antagonist at alpha-adrenergic, histamine H1, cholinergic, and other dopaminergic and serotonergic receptors.

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Oral:

Bipolar disorder, acute mania: Initial effects may be observed within days of treatment with continued improvements over 1 to 2 weeks (Goikolea 2013; Tohen 2000; Welten 2016).

Parkinson disease psychosis: Initial effects may be observed within 1 week with continued improvements over 2 to 3 months (Pintor 2012; Pollak 2004).

Schizophrenia: Initial effects may be observed within 1 to 2 weeks of treatment with continued improvements through 4 to 8 weeks (Adnan 2022; Agid 2003; Levine 2010). The slow titration of clozapine delays time to therapeutic dose. As a result, trials longer than 8 weeks are recommended (CPA [Remington 2017]).

Duration of action: Variable.

Protein binding: 97% to serum proteins.

Metabolism: Extensively hepatic via CYP1A2 (primary), 2C19, 3A4 and 2D6; forms metabolites with limited (desmethyl metabolite) or no activity (hydroxylated and N-oxide derivative derivatives). Note: A pediatric pharmacokinetic study (n=6; age: 9 to 16 years) found higher concentrations of the desmethyl metabolite in comparison to clozapine (especially in females) when compared to data from adult studies; the authors suggest that both the parent drug and desmethyl metabolite contribute to the efficacy and adverse effect profile in children and adolescents (Frazier 2003; Sheehan 2010).

Bioavailability: 27% to 50% (not affected by food); orally disintegrating tablets, regular tablets, and oral suspension are bioequivalent (Gareri 2003; Guitton 1998).

Half-life elimination: Steady state: 12 hours (range: 4 to 66 hours).

Time to peak: Suspension: 2.2 hours (range: 1 to 3.5 hours); Tablets: 2.5 hours (range: 1 to 6 hours); Orally disintegrating tablets: 2.3 hours (range: 1 to 6 hours).

Excretion: Urine (~50%) and feces (30%) with trace amounts of unchanged drug.

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: Clozapine concentrations may be increased.

Hepatic function impairment: Clozapine concentrations may be increased.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Clozaril | Leponex;
  • (AR) Argentina: Clozapina Fabra | Clozapina Lemax | Clozapina Rospaw | Lapenax | Sequax;
  • (AT) Austria: Clozapin accord | Lanolept | Leponex;
  • (AU) Australia: Clopine | Clozapine synthon | Clozaril | Clozitor | Versacloz;
  • (BD) Bangladesh: Sensipin | Sizopin | Zapenia;
  • (BE) Belgium: Leponex;
  • (BG) Bulgaria: Clozapine accord | Excloza | Leponex | Xenopal | Xenopalan;
  • (BR) Brazil: Clozapina | Leponex | Okotico | Pinazan | Xynaz | Zolapin;
  • (CH) Switzerland: Clopin eco | Clozapin mepha | Clozapin viatris | Leponex;
  • (CL) Chile: Dicomex | Leponex | Lodux;
  • (CO) Colombia: Clofax | Clozapina | Clozapina mk | Clozaren | Dicomex | Discole | Drugtech dicomex | Labincloz | Leponex | Sicozapina | Tanyl | Zapen;
  • (CZ) Czech Republic: Alemoxan | Clozapin | Clozapin sandoz | Leponex;
  • (DE) Germany: Clozapin | Clozapin 1a pharma | Clozapin al | Clozapin beta | Clozapin Biomo | Clozapin ct | Clozapin glenmark | Clozapin hexal | Clozapin neuraxpharm | Clozapin puren | Clozapin ratiopharm | Clozapin sandoz | Elcrit | Leponex;
  • (DK) Denmark: Clozapin 2care4 | Clozapin hexal;
  • (DO) Dominican Republic: Atipil | Clopsine | Leponex | Tibuza;
  • (EC) Ecuador: Clopsine | Clozapina | Leponex | Luverina | Refraxol | Zapen;
  • (EE) Estonia: Clozapine accord | Leponex;
  • (EG) Egypt: Clozapex | Leponex | Medazepine | Schizonex | Zaclo;
  • (ES) Spain: Clozapin stada | Clozapina aurovitaS | Clozapina stada | Leponex | Nemea | Nemea EFG;
  • (FI) Finland: Clozapin hexal | Clozapine accord | Clozapine alpharma | Froidir | Leponex;
  • (FR) France: Clozapine accord | Clozapine arrow | Clozapine eg | Clozapine Merck | Clozapine Panpharma | Clozapine teva | Clozapine zentiva | Leponex;
  • (GB) United Kingdom: Clozaril | Denzapine | Zaponex;
  • (GR) Greece: Leponex;
  • (HK) Hong Kong: Clopine | Clozaril;
  • (HR) Croatia: Clozapine Remedica | Leponex | Sanosen | Zaniq;
  • (HU) Hungary: Alemoxan | Clozapine Gerot | Leponex;
  • (ID) Indonesia: Clopine | Clorilex | Clozaril | Leponex | Lozap | Nuzip | Sizoril;
  • (IE) Ireland: Clozaril | Denzapine;
  • (IL) Israel: Leponex | Lozapine;
  • (IN) India: Chrozap | Cipin 100 | Clomach | Clopin | Cloza | Clozabest | Clozamat | Klopin | Kloza | Lozapin | Neuropin | Pilzep | Psyclo | Psycloze | Pyne | Refract | Sizopin | Skizoril | Soloquin | Syclop | Vizonic | Zaporil | Zopin;
  • (IT) Italy: Clozapina | Clozapina accord | Clozapina aurobindo | Clozapina doc | Clozapina Orion | Clozapina Teva | Leponex;
  • (JO) Jordan: Leponex;
  • (JP) Japan: Clozaril;
  • (KE) Kenya: Leponex | Moclopin;
  • (KR) Korea, Republic of: Clozaril | Clzapin | Clzapine;
  • (LB) Lebanon: Lanolept | Leponex;
  • (LT) Lithuania: Azaleptin | Clozapine accord | Leponex;
  • (LU) Luxembourg: Leponex;
  • (LV) Latvia: Azaleptin | Clozapin | Clozapine accord | Leponex;
  • (MA) Morocco: Leponex;
  • (MX) Mexico: Clopsine | Leponex | Sicrep;
  • (MY) Malaysia: Anzapine | Anzaril | Clopine | Clozarem | Clozaril;
  • (NG) Nigeria: Xycloza;
  • (NL) Netherlands: Clozapine Auro | Clozapine cf | Clozapine Glenmark | Clozapine leyden delta | Clozapine PCH | Leponex | Zaponex;
  • (NO) Norway: Clozapin hexal | Clozapin neuraxpharm | Leponex;
  • (NZ) New Zealand: Clopine | Clozaril | Versacloz;
  • (PE) Peru: Clopsine | Clozapina | Epizol | Leponex | Refraxol;
  • (PH) Philippines: Clopixene | Ihope | Leponex | Nirva | Sizopin | Syclop | Ziproc;
  • (PK) Pakistan: Amlepo | Bio zapine | Caliana | Carapine | Cepin | Cloprex | Clozamed | Clozaril | Clozcare | Ekloz | Glipin | Saveril | Welzapine;
  • (PL) Poland: Clopizam | Klozapol | Leponex | Symcloza;
  • (PR) Puerto Rico: Clozaril | Fazaclo;
  • (PT) Portugal: Clozapina | Clozapina Generis | Clozapina Mylan | Clozapina ratiopharm | Leponex | Ozapim;
  • (PY) Paraguay: Clozapin quimfa | Clozapina celsius | Dicomex | Luverina;
  • (QA) Qatar: Clozarem | Leponex;
  • (RU) Russian Federation: Azaleprol | Azalepticon | Azaleptin | Closastene | Clozapin | Clozapin Avexima | Clozapinum | Leponex;
  • (SA) Saudi Arabia: Leponex;
  • (SE) Sweden: Clozapine accord | Clozapine actavis | Clozapine mylan | Clozapine orifarm | Clozapine sandoz | Clozapine teva | Froidir | Leponex;
  • (SG) Singapore: Clozaril;
  • (SI) Slovenia: Leponex;
  • (SK) Slovakia: Clozapine accord | Leponex;
  • (TH) Thailand: Clopaze | Cloril | Clozamed | Clozaril;
  • (TN) Tunisia: Leponex;
  • (TR) Turkey: Clonex | Leponex;
  • (TW) Taiwan: Clopine | Closian | Clozaril | Mezapin | Uspen | Zapine;
  • (UA) Ukraine: Asaleptolum | Azaleptin | Azaleptol | Azapin | Clozapin sandoz | Leponex;
  • (UY) Uruguay: Leponex | Luverina;
  • (VE) Venezuela, Bolivarian Republic of: Clozapina | Leponex;
  • (VN) Viet Nam: Clozapyl | Dafidi;
  • (ZA) South Africa: Aspen Clozapine | Cloment | Leponex
  1. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
  2. Adnan M, Motiwala F, Trivedi C, Sultana T, Mansuri Z, Jain S. Clozapine for management of childhood and adolescent-onset schizophrenia: a systematic review and meta-analysis. J Child Adolesc Psychopharmacol. 2022;32(1):2-11. doi:10.1089/cap.2021.0092 [PubMed 35099269]
  3. Agelink MW, Majewski T, Wurthmann C, et al. Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol. 2001;21(1):8-13. doi:10.1097/00004714-200102000-00003 [PubMed 11199953]
  4. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry. 2003;60(12):1228-1235. doi:10.1001/archpsyc.60.12.1228 [PubMed 14662555]
  5. Alfaro CL, Wudarsky M, Nicolson R, et al, "Correlation of Antipsychotic and Prolactin Concentrations in Children and Adolescents Acutely Treated With Haloperidol, Clozapine or Olanzapine," J Child Adolesc Psychopharmacol, 2002, 12(2):83-91. [PubMed 12188977]
  6. Alonso-Pedrero L, Bes-Rastrollo M, Marti A. Effects of antidepressant and antipsychotic use on weight gain: a systematic review. Obes Rev. 2019;20(12):1680-1690. doi:10.1111/obr.12934 [PubMed 31524318]
  7. Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf. 2010;5(1):97-104. doi:10.2174/157488610789869265 [PubMed 20210726]
  8. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993;329(3):162-167. doi:10.1056/NEJM199307153290303 [PubMed 8515788]
  9. American College of Obstetricians and Gynecologists (ACOG). Treatment and management of mental health conditions during pregnancy and postpartum: ACOG clinical practice guideline no. 5. Obstet Gynecol. 2023;141(6):1262-1288. doi:10.1097/AOG.0000000000005202 [PubMed 37486661]
  10. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601. doi:10.2337/diacare.27.2.596 [PubMed 14747245]
  11. American Diabetes Association (ADA), American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65(2):267-272. [PubMed 15003083]
  12. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. American Journal of Psychiatry. 2002;159(4 Suppl):1-50. [PubMed 11958165]
  13. Annamalai A, Kosir U, Tek C. Prevalence of obesity and diabetes in patients with schizophrenia. World J Diabetes. 2017;8(8):390-396. doi:10.4239/wjd.v8.i8.390 [PubMed 28861176]
  14. Anzai T, Takahashi K, Watanabe M. Adverse reaction reports of neuroleptic malignant syndrome induced by atypical antipsychotic agents in the Japanese Adverse Drug Event Report (JADER) database. Psychiatry Clin Neurosci. 2019;73(1):27-33. doi:10.1111/pcn.12793 [PubMed 30375086]
  15. Arranz MJ, Dawson E, Shaikh S, et al. Cytochrome P4502D6 genotype does not determine response to clozapine. Br J Clin Pharmacol. 1995;39(4):417-420. [PubMed 7640149]
  16. Au AF, Luthra V, Stern R. Clozapine-induced acute interstitial nephritis. Am J Psychiatry. 2004;161(8):1501. doi:10.1176/appi.ajp.161.8.1501 [PubMed 15285988]
  17. Augustin NB, Maroules M. Hyperleukocytosis during clozapine treatment: a rare presentation of B-cell Acute lymphoblastic leukemia [published correction appears in Leuk Res Rep. 2022;17:100307]. Leuk Res Rep. 2021;15:100253. doi:10.1016/j.lrr.2021.100253 [PubMed 34141565]
  18. Ayaydin H, Ulgar SB. Control of seizures in a clozapine-treated schizophrenia patient, using valproate: a case report. Psychiatry and Clinical Psychopharmacology. 2019;29(4):529-532. doi:10.1080/24750573.2018.1468640
  19. Bark N. Deaths of psychiatric patients during heat waves. Psychiatr Serv. 1998;49(8):1088-1090. doi:10.1176/ps.49.8.1088 [PubMed 9712220]
  20. Barnas C, Bergant A, Hummer M, et al, "Clozapine Concentrations in Maternal and Fetal Plasma, Amniotic Fluid, and Breast Milk," Am J Psychiatry, 1994, 151(6):945. [PubMed 8185013]
  21. Barnes TR, Drake R, Paton C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020;34(1):3-78. doi:10.1177/0269881119889296 [PubMed 31829775]
  22. Beex-Oosterhuis MM, Van Gool AR, Heerdink ER, van Kesteren C, van Marum RJ. Clozapine treatment during pregnancy and the postpartum period: a systematic literature review. J Clin Psychiatry. 2021;83(1):21r13952. doi:10.4088/JCP.21r13952 [PubMed 34905664]
  23. Bellissima BL, Tingle MD, Cicović A, Alawami M, Kenedi C. A systematic review of clozapine-induced myocarditis [published correction appears in Int J Cardiol. 2018 Apr 11]. Int J Cardiol. 2018;259:122-129. doi:10.1016/j.ijcard.2017.12.102 [PubMed 29579587]
  24. Belteczki Z, Ujvari J, Dome P. Clozapine withdrawal-induced malignant catatonia or neuroleptic malignant syndrome: a case report and a brief review of the literature. Clin Neuropharmacol. 2021;44(4):148-153. doi:10.1097/WNF.0000000000000462 [PubMed 34132673]
  25. Belvederi Murri M, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R D. 2015;15(1):45-62. doi:10.1007/s40268-014-0078-0 [PubMed 25578944]
  26. Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. Clin Pharmacokinet. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7 [PubMed 29441476]
  27. Bishara D, Taylor D. Adverse effects of clozapine in older patients: epidemiology, prevention and management. Drugs Aging. 2014;31(1):11-20. doi:10.1007/s40266-013-0144-2 [PubMed 24338220]
  28. Blackman G, Kapila A, Grosskopf CM, Dratcu L. Focussing on the fundaments - assessing and treating clozapine induced gastrointestinal hypomotility. Int J Psychiatry Clin Pract. 2020;24(1):18-19. doi:10.1080/13651501.2019.1710538 [PubMed 31910056]
  29. Bloechliger M, Rüegg S, Jick SS, Meier CR, Bodmer M. Antipsychotic drug use and the risk of seizures: follow-up study with a nested case-control analysis. CNS Drugs. 2015;29(7):591-603. doi:10.1007/s40263-015-0262-y [PubMed 26242478]
  30. Bobo WV, Stovall JA, Knostman M, et al. Converting From Brand-Name to Generic Clozapine: A Review of Effectiveness and Tolerability Data. Am J Health Syst Pharm. 2010;67(1):27-37. [PubMed 20044366]
  31. Bolu A, Akarsu S, Pan E, Aydemir E, Oznur T. Low-dose Clozapine-induced seizure: a case report. Clin Psychopharmacol Neurosci. 2017;15(2):190-193. doi:10.9758/cpn.2017.15.2.190 [PubMed 28449570]
  32. Bouchama A, Dehbi M, Mohamed G, Matthies F, Shoukri M, Menne B. Prognostic factors in heat wave related deaths: a meta-analysis. Arch Intern Med. 2007;167(20):2170-2176. doi:10.1001/archinte.167.20.ira70009 [PubMed 17698676]
  33. Bruno V, Valiente-Gómez A, Alcoverro O. Clozapine and fever: a case of continued therapy with clozapine. Clin Neuropharmacol. 2015;38(4):151-153. doi:10.1097/WNF.0000000000000088 [PubMed 26166236]
  34. Burk BG, Ward AH, Clark B. A case report of acute hypothermia during initial inpatient clozapine titration with review of current literature on clozapine-induced temperature dysregulations. BMC Psychiatry. 2020;20(1):290. doi:10.1186/s12888-020-02695-w [PubMed 32517724]
  35. Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry. 2005;50(13)(suppl 1):7S-57S. [PubMed 16529334]
  36. Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):e264-e278. doi:10.4088/JCP.16r10832 [PubMed 28146614]
  37. Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29(1):127-viii. doi:10.1016/j.ncl.2010.10.002 [PubMed 21172575]
  38. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004;65 Suppl 7:4-20. [PubMed 15151456]
  39. Catalano G, Catalano MC, Frankel Wetter RL. Clozapine induced polyserositis. Clin Neuropharmacol. 1997;20(4):352-356. doi:10.1097/00002826-199708000-00007 [PubMed 9260733]
  40. Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs. 2013;27(7):545-572. doi: 10.1007/s40263-013-0079-5. [PubMed 23821039]
  41. Chang A, Krygier DS, Chatur N, Yoshida EM. Clozapine-induced fatal fulminant hepatic failure: a case report. Can J Gastroenterol. 2009;23(5):376-378. doi:10.1155/2009/503916 [PubMed 19440569]
  42. Chaplin AC, Curley MA, Wanless IR. Re: Recent case report of clozapine-induced acute hepatic failure. Can J Gastroenterol. 2010;24(12):739-741. doi:10.1155/2010/535026 [PubMed 21165382]
  43. Chatterton R. Eosinophilia after commencement of clozapine treatment. Aust N Z J Psychiatry. 1997;31(6):874-876. doi:10.3109/00048679709065515 [PubMed 9483262]
  44. Chengappa KNR, Thomas J, Kahn CE, et al. COVID-19 infection, fluctuations in the clozapine/norclozapine levels and metabolic ratio and clozapine toxicity: an illustrative case-report. Schizophr Res. 2022;244:66-68. doi:10.1016/j.schres.2022.05.009 [PubMed 35605549]
  45. Chew ML, Mulsant BH, Pollock BG, et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res. 2006;88(1-3):63-72. doi:10.1016/j.schres.2006.07.011 [PubMed 16928430]
  46. Cho J, Hayes RD, Jewell A, et al. Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study. Acta Psychiatr Scand. 2019;139(3):237-247. doi:10.1111/acps.12989 [PubMed 30478891]
  47. Chrétien B, Lelong-Boulouard V, Chantepie S, et al. Haematologic malignancies associated with clozapine v. all other antipsychotic agents: a pharmacovigilance study in VigiBase®. Psychol Med. 2021;51(9):1459-1466. doi:10.1017/S0033291720000161 [PubMed 32036793]
  48. Citrome L, Holt RI, Walker DJ, Hoffmann VP. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin Drug Investig. 2011;31(7):455-482. doi:10.2165/11589060-000000000-00000 [PubMed 21495734]
  49. Clark SR, Warren NS, Kim G, et al. Elevated clozapine levels associated with infection: A systematic review. Schizophr Res. 2017. pii: S0920-9964(17)30185-30188. doi: 10.1016/j.schres.2017.03.045. [PubMed 28392207]
  50. Clozapine [prescribing information]. Greenville, NC: Mayne Pharma; June 2017.
  51. Clozapine orally disintegrating tablets [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; April 2023.
  52. Clozaril (clozapine) [prescribing information]. Rosemont, PA: HLS Therapeutics (USA) Inc; January 2025.
  53. Clozaril (clozapine) [product monograph]. Etobicoke, Ontario, Canada: HLS Therapeutics Inc; April 2022.
  54. Cohen D. Clozapine and gastrointestinal hypomotility. CNS Drugs. 2017;31(12):1083-1091. doi: 10.1007/s40263-017-0481-5. [PubMed 29230675]
  55. Cohen H, Loewenthal U, Matar M, Kotler M. Association of autonomic dysfunction and clozapine. Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication. Br J Psychiatry. 2001;179:167-171. doi:10.1192/bjp.179.2.167 [PubMed 11483480]
  56. Corallo CE, Ernest D. Atypical neuroleptic malignant syndrome with long-term clozapine. Crit Care Resusc. 2007;9(4):338-340. [PubMed 18052897]
  57. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents [published correction appears in JAMA. 2009;302(21):2322]. JAMA. 2009;302(16):1765-1773. doi:10.1001/jama.2009.1549 [PubMed 19861668]
  58. Correll CU, Penzner JB, Parikh UH, et al, "Recognizing and Monitoring Adverse Events of Second-Generation Antipsychotics in Children and Adolescents," Child Adolesc Psych Clin N Am, 2006, 15(1):177-206. [PubMed 16321730]
  59. Costa-Dookhan KA, Agarwal SM, Chintoh A, et al. The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy. Expert Opin Drug Saf. 2020;19(1):43-57. doi:10.1080/14740338.2020.1698545 [PubMed 31770500]
  60. Crouse EL, Alastanos JN, Bozymski KM, Toscano RA. Dysphagia with second-generation antipsychotics: a case report and review of the literature. Ment Health Clin. 2018;7(2):56-64. doi:10.9740/mhc.2017.03.056 [PubMed 29955499]
  61. Damkier P, Videbech P. The safety of second-generation antipsychotics during pregnancy: a clinically focused review. CNS Drugs. 2018;32(4):351-366. doi:10.1007/s40263-018-0517-5 [PubMed 29637530]
  62. Datta T, Solomon AJ. Clozapine-induced myocarditis. Oxf Med Case Reports. 2018;2018(1):omx080. doi:10.1093/omcr/omx080 [PubMed 29345690]
  63. Davis EAK, Kelly DL. Clozapine-associated renal failure: a case report and literature review. Ment Health Clin. 2019;9(3):124-127. doi:10.9740/mhc.2019.05.124 [PubMed 31123659]
  64. Davydov L, Botts SR. Clozapine-induced hypersalivation. Ann Pharmacother. 2000;34(5):662-665. doi:10.1345/aph.19259 [PubMed 10852096]
  65. Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231-2241. doi:10.2147/NDT.S113099 [PubMed 28883731]
  66. De Berardis D, Rapini G, Olivieri L, et al. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Ther Adv Drug Saf. 2018;9(5):237-256. doi:10.1177/2042098618756261 [PubMed 29796248]
  67. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011b;8(2):114-126. doi:10.1038/nrendo.2011.156 [PubMed 22009159]
  68. De Hert M, Hudyana H, Dockx L, et al. Second-generation antipsychotics and constipation: a review of the literature. Eur Psychiatry. 2011a;26(1):34-44. [PubMed 20542667]
  69. de Leon J, Susce MT, Johnson M, et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res. 2007;92(1-3):95-102. doi:10.1016/j.schres.2007.01.015 [PubMed 17346932]
  70. Dean L. Clozapine therapy and CYP2D6, CYP1A2, and CYP3A4 Genotypes. In: Pratt V, ed. Medical Genetics Summaries. Bethesda, MD: National Center for Biotechnology Information (US); 2012.
  71. Delgado A, Velosa J, Zhang J, Dursun SM, Kapczinski F, de Azevedo Cardoso T. Clozapine in bipolar disorder: a systematic review and meta-analysis. J Psychiatr Res. 2020;125:21-27. doi:10.1016/j.jpsychires.2020.02.026 [PubMed 32182485]
  72. DeRemer CE, Andrick BJ, Capito MD. Clozapine drug-induced pancreatitis of intermediate latency of onset confirmed by de-challenge and re-challenge . Int J Clin Pharmacol Ther. 2019;57(1):37-40. doi:10.5414/CP203314 [PubMed 30336807]
  73. Dev VJ, Krupp P. Adverse event profile and safety of clozapine. Rev Contemp Pharmacother. 1995;6:197–208.
  74. Dewan V, Roth BA. Antipsychotic-induced QTc interval prolongation. Can J Psychiatry. 2004;49(9):646. doi:10.1177/070674370404900923 [PubMed 15503744]
  75. Dimitri Valente G, Dusi N, Lasalvia A. An idiosyncratic, acute, systemic, and life-threatening adverse reaction in a young patient treated with clozapine: a case report. J Clin Psychopharmacol. 2018;38(4):387-389. doi:10.1097/JCP.0000000000000900 [PubMed 29901563]
  76. Domecq JP, Prutsky G, Leppin A, et al. Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(2):363-370. doi:10.1210/jc.2014-3421 [PubMed 25590213]
  77. Donizete da Costa F, Toledo da Silva Antonialli K, Dalgalarrondo P. Priapism and clozapine use in a patient with hypochondriacal delusional syndrome. Oxf Med Case Reports. 2015;2015(3):229-231. doi:10.1093/omcr/omv020 [PubMed 26634131]
  78. Driver DI, Gogtay N, Rapoport JL. Childhood onset schizophrenia and early onset schizophrenia spectrum disorders. Child Adolesc Psychiatr Clin N Am. 2013;22(4):539-555. doi:10.1016/j.chc.2013.04.001 [PubMed 24012072]
  79. Eap CB, Bender S, Jaquenoud Sirot E, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol. 2004;24(2):214-219. [PubMed 15206669]
  80. El Ouni Amami N, Ali-Diabacte H, Ateb S, et al. Clozapine-induced cholinergic urticaria: a case report. Ther Adv Psychopharmacol. 2024;14:20451253241241056. doi:10.1177/20451253241241056 [PubMed 38745850]
  81. Ellfolk M, Leinonen MK, Gissler M, Kiuru-Kuhlefelt S, Saastamoinen L, Malm H. Second-generation antipsychotic use during pregnancy and risk of congenital malformations. Eur J Clin Pharmacol. 2021;77(11):1737-1745. doi:10.1007/s00228-021-03169-y [PubMed 34100993]
  82. Ely SF, Neitzel AR, Gill JR. Fatal diabetic ketoacidosis and antipsychotic medication. J Forensic Sci. 2013;58(2):398-403. doi:10.1111/1556-4029.12044 [PubMed 23278567]
  83. Evcimen H, Alici-Evcimen Y, Basil B, Mania I, Mathews M, Gorman JM. Neuroleptic malignant syndrome induced by low dose aripiprazole in first episode psychosis. J Psychiatr Pract. 2007;13(2):117-119. doi:10.1097/01.pra.0000265770.17871.01 [PubMed 17414689]
  84. Every-Palmer S, Inns SJ, Grant E, Ellis PM. Effects of clozapine on the gut: cross-sectional study of delayed gastric emptying and small and large intestinal dysmotility. CNS Drugs. 2019;33(1):81-91. doi:10.1007/s40263-018-0587-4 [PubMed 30456745]
  85. Every-Palmer S, Nowitz M, Stanley J, et al. Clozapine-treated patients have marked gastrointestinal hypomotility, the probable basis of life-threatening gastrointestinal complications: a cross sectional study. EBioMedicine. 2016;5:125-134. [PubMed 27532076]
  86. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  87. Farah RE, Makhoul NM, Farah RE, Shai MD. Fatal venous thromboembolism associated with antipsychotic therapy. Ann Pharmacother. 2004;38(9):1435-1438. doi:10.1345/aph.1E021 [PubMed 15280515]
  88. Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol. 2013;20(1):5-15. doi:10.1111/j.1468-1331.2012.03866.x [PubMed 23279439]
  89. Findling RL, Biederman J, Wilens TE, et al. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr. 2005;147(3):348-354. doi:10.1016/j.jpeds.2005.03.014 [PubMed 16182674]
  90. Findling RL, Frazier JA, Gerbino-Rosen B, et al, "Is There a Role for Clozapine in the Treatment of Children and Adolescents?" J Am Acad Child Adolesc Psych, 2007, 46(3):423-8. [PubMed 17314729]
  91. Fleischhaker C, Heiser P, Hennighausen K, et al. Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. J Neural Transm (Vienna). 2007;114(2):273-280. doi:10.1007/s00702-006-0602-7 [PubMed 17109073]
  92. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA provides update on patient access to certain REMS drugs during COVID-19 public health emergency. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-provides-update-patient-access-certain-rems-drugs-during-covid-19. Published March 22, 2020. Accessed March 27, 2020.
  93. Fraguas D, Correll CU, Merchán-Naranjo J, et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol. 2011;21(8):621-645. doi:10.1016/j.euroneuro.2010.07.002 [PubMed 20702068]
  94. Frazier JA, Cohen LG, Jacobsen L, et al. Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. J Clin Psychopharmacol. 2003;23(1):87-91. [PubMed 12544379]
  95. Freudenreich O, McEvoy J. Schizophrenia in adults: guidelines for prescribing clozapine. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 7, 2024.
  96. Freudenreich O, Goff DC. Colon perforation and peritonitis associated with clozapine. J Clin Psychiatry. 2000;61(12):950-951. doi:10.4088/jcp.v61n1210e [PubMed 11206605]
  97. Frieling H, Hillemacher T, Ziegenbein M, Neundörfer B, Bleich S. Treating dopaminergic psychosis in Parkinson’s disease: structured review and meta-analysis. Eur Neuropsychopharmacol. 2007;17(3):165-171. doi:10.1016/j.euroneuro.2006.08.007 [PubMed 17070675]
  98. Fuller MA, Borovicka MC, Jaskiw GE, Simon MR, Kwon K, Konicki PE. Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. J Clin Psychiatry. 1996;57(11):514-518. doi:10.4088/jcp.v57n1102 [PubMed 8968299]
  99. Gaertner I, Altendorf K, Batra A, Gaertner HJ. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses. J Clin Psychopharmacol. 2001a;21(2):215-222. doi:10.1097/00004714-200104000-00014 [PubMed 11270919]
  100. Gaertner I, Gaertner HJ, Vonthein R, Dietz K. Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J Clin Psychopharmacol. 2001b;21(3):305-310. doi:10.1097/00004714-200106000-00010 [PubMed 11386494]
  101. Gambassi G, Capurso S, Tarsitani P, Liperoti R, Bernabei R. Fatal neuroleptic malignant syndrome in a previously long-term user of clozapine following its reintroduction in combination with paroxetine. Aging Clin Exp Res. 2006;18(3):266-270. doi:10.1007/BF03324659 [PubMed 16804375]
  102. Gareri P, De Fazio P, Manfredi VG, De Sarro G. Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. J Clin Psychopharmacol. 2014;34(1):109-123. doi:10.1097/JCP.0b013e3182a6096e [PubMed 24158020]
  103. Gareri P, De Fazio P, Russo E, et al. The Safety of Clozapine in the Elderly. Expert Opin Drug Saf. 2008;7(5):525-38. [PubMed 18759705]
  104. Gareri P, De Fazio P, Stilo M, Ferreri G, De Sarro G. Conventional and atypical antipsychotics in the elderly: a review. Clin Drug Investig. 2003;23(5):287-322. [PubMed 17535043]
  105. Garg A, Bath AS, Kalavakunta JK. Non-ischemic cardiomyopathy: a rare adverse effect of clozapine. Cureus. 2020;12(4):e7901. doi:10.7759/cureus.7901 [PubMed 32494516]
  106. Gen-Clozapine [product monograph]. Etobicoke, Ontario, Canada: Mylan Pharmaceuticals ULC; February 2014.
  107. Gerbino-Rosen G, Roofeh D, Tompkins DA, et al, "Hematological Adverse Events in Clozapine-Treated Children and Adolescents," J Am Acad Child Adolesc Psychiatry, 2005, 44(10):1024-31. [PubMed 16175107]
  108. Gerlach J, Lublin H, Peacock L. Extrapyramidal symptoms during long-term treatment with antipsychotics: special focus on clozapine and D1 and D2 dopamine antagonists. Neuropsychopharmacology. 1996;14(3 suppl):35S-39S. doi:10.1016/0893-133X(95)00203-P [PubMed 8866742]
  109. Gerlach J, Peacock L. Motor and mental side effects of clozapine. J Clin Psychiatry. 1994;55 Suppl B:107-109. [PubMed 7961551]
  110. Ghoneim AM, Mansour SM. The effect of liver and kidney disease on the pharmacokinetics of clozapine and sildenafil: a physiologically based pharmacokinetic modeling. Drug Des Devel Ther. 2020;14:1469-1479. doi:10.2147/DDDT.S246229 [PubMed 32341640]
  111. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775-786. doi:10.7326/0003-4819-146-11-200706050-00006 [PubMed 17548409]
  112. Goikolea JM, Colom F, Capapey J, et al. Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania. Eur Neuropsychopharmacol. 2013;23(4):305-316. doi:10.1016/j.euroneuro.2012.05.017 [PubMed 22841129]
  113. Goldstein JI, Jarskog LF, Hilliard C, et al. Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nat Commun. 2014;5:4757. doi:10.1038/ncomms5757 [PubMed 25187353]
  114. Gorup E, Rifel J, Petek Šter M. Anticholinergic burden and most common anticholinergic-acting medicines in older general practice patients. Zdr Varst. 2018;57(3):140-147. doi:10.2478/sjph-2018-0018 [PubMed 29983780]
  115. Goyal N, Praharaj SK, Desarkar P, Nizamie H. Electroencephalographic abnormalities in clozapine-treated patients: a cross-sectional study. Psychiatry Investig. 2011;8(4):372-376. doi:10.4306/pi.2011.8.4.372 [PubMed 22216049]
  116. Green AI, Tohen M, Patel JK, et al. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry. 2000;157(6):982-986. doi: 10.1176/appi.ajp.157.6.982. [PubMed 10831480]
  117. Grover S, Hazari N, Chakrabarti S, Avasthi A. Association of clozapine with seizures: a brief report involving 222 patients prescribed clozapine. East Asian Arch Psychiatry. 2015;25(2):73-78. [PubMed 26118746]
  118. Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry. 2009;10(2):85-116. doi:10.1080/15622970902823202 [PubMed 19347775]
  119. Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. CNS Drugs. 2011;25(8):659-671. doi:10.2165/11591710-000000000-00000 [PubMed 21790209]
  120. Guitton C, Abbar M, Kinowski JM, et al. Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol. 1998;18(6):470-476. [PubMed 9864080]
  121. Gurrera RJ, Gearin PF, Love J, et al. Recognition and management of clozapine adverse effects: a systematic review and qualitative synthesis. Acta Psychiatr Scand. 2022;145(5):423-441. doi:10.1111/acps.13406 [PubMed 35178700]
  122. Gurrera RJ, Parlee AC, Perry NL. Aspiration pneumonia, an unappreciated risk of clozapine treatment. J Clin Psychopharmacol. 2016;36(2):174-176. [PubMed 26848787]
  123. Hägg S, Spigset O, Söderström TG. Association of venous thromboembolism and clozapine. Lancet. 2000;355(9210):1155-1156. doi:10.1016/S0140-6736(00)02066-3 [PubMed 10791380]
  124. Hansen A, Bi P, Nitschke M, Ryan P, Pisaniello D, Tucker G. The effect of heat waves on mental health in a temperate Australian city. Environ Health Perspect. 2008;116(10):1369-1375. doi:10.1289/ehp.11339 [PubMed 18941580]
  125. Hasan A, Falkai P, Wobrock T, et al; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318-378. doi: 10.3109/15622975.2012.696143. [PubMed 22834451]
  126. Hasnain M, Vieweg WV. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs. 2014;28(10):887-920. doi:10.1007/s40263-014-0196-9 [PubMed 25168784]
  127. Hayes RD, Downs J, Chang CK, et al. The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders. Schizophr Bull. 2015;41(3):644-655. doi:10.1093/schbul/sbu120 [PubMed 25154620]
  128. Healthy Canadians Recalls & Alerts: Summary Safety Review - Atypical antipsychotics - assessing the potential risk of sleep apnoea. Health Canada website. https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-atypical-antipsychotics-assessing-potential-risk-sleep-apnoea.html. Published August 16, 2016. Accessed August 23, 2016.
  129. Hedges D, Jeppson K, Whitehead P. Antipsychotic medication and seizures: a review. Drugs Today (Barc). 2003;39(7):551-557. doi:10.1358/dot.2003.39.7.799445 [PubMed 12973403]
  130. Heinonen E, Forsberg L, Nörby U, Wide K, Källén K. Antipsychotic use during pregnancy and risk for gestational diabetes: a national register-based cohort study in Sweden. CNS Drugs. 2022;36(5):529-539. doi:10.1007/s40263-022-00908-2 [PubMed 35220525]
  131. Henderson DC. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. J Clin Psychiatry. 2001;62 Suppl 23:39-44. [PubMed 11603884]
  132. Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry. 2005;66(9):1116-1121. doi:10.4088/jcp.v66n0905 [PubMed 16187768]
  133. Herzig SJ, LaSalvia MT, Naidus E, et al. Antipsychotics and the risk of aspiration pneumonia in individuals hospitalized for nonpsychiatric conditions: a cohort study. J Am Geriatr Soc. 2017;65(12):2580-2586. doi:10.1111/jgs.15066. [PubMed 29095482]
  134. Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1-02):9-62. doi: 10.1055/s-0043-116492. [PubMed 28910830]
  135. Hinze-Selch D, Becker EW, Stein G, Schreiber W, Pollmächer T. Clozapine-induced parotitis: an immunological cause? Am J Psychiatry. 1996;153(6):840. doi:10.1176/ajp.153.6.840a [PubMed 8633706]
  136. Hoffmann MS, Oliveira LM, Lobato MI, Belmonte-de-Abreu P. Heat stroke during long-term clozapine treatment: should we be concerned about hot weather? Trends Psychiatry Psychother. 2016;38(1):56-59. doi:10.1590/2237-6089-2015-0066 [PubMed 27074342]
  137. Howanitz E, Pardo M, Smelson DA, et al. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. J Clin Psychiatry. 1999;60(1):41-44. [PubMed 10074877]
  138. Howard R, Rabins PV, Seeman MV, Jeste DV. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. Am J Psychiatry. 2000;157(2):172-178. doi:10.1176/appi.ajp.157.2.172 [PubMed 10671383]
  139. Hrdlicka M, Zedkova I, Blatny M, Urbanek T. Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: a retrospective study. Neuro Endocrinol Lett. 2009;30(2):256-261. [PubMed 19675512]
  140. Hsu JH, Mulsant BH, Lenze EJ, et al. Clinical predictors of extrapyramidal symptoms associated with aripiprazole augmentation for the treatment of late-life depression in a randomized controlled trial. J Clin Psychiatry. 2018;79(4):17m11764. doi:10.4088/JCP.17m11764 [PubMed 29924506]
  141. Hummer M, Kurz M, Kurzthaler I, Oberbauer H, Miller C, Fleischhacker WW. Hepatotoxicity of clozapine. J Clin Psychopharmacol. 1997;17(4):314-317. doi:10.1097/00004714-199708000-00012 [PubMed 9241012]
  142. Hung YP, Wang CS, Yen CN, et al. Role of cytokine changes in clozapine-induced fever: a cohort prospective study. Psychiatry Clin Neurosci. 2017;71(6):395-402. doi:10.1111/pcn.12508 [PubMed 28106314]
  143. Huybrechts KF, Hernández-Díaz S, Patorno E, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry. 2016;73(9):938-946. doi:10.1001/jamapsychiatry.2016.1520 [PubMed 27540849]
  144. Huybrechts KF, Straub L, Karlsson P, et al. Association of in utero antipsychotic medication exposure with risk of congenital malformations in Nordic countries and the US. JAMA Psychiatry. 2023;80(2):156-166. doi:10.1001/jamapsychiatry.2022.4109 [PubMed 36477338]
  145. Imaz ML, Oriolo G, Torra M, Soy D, García-Esteve L, Martin-Santos R. Clozapine use during pregnancy and lactation: a case-series report. Front Pharmacol. 2018;9:264. doi:10.3389/fphar.2018.00264 [PubMed 29636684]
  146. Jackson JW, Schneeweiss S, VanderWeele TJ, Blacker D. Quantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: systematic review and meta-synthesis. PLoS One. 2014;9(8):e105376. doi:10.1371/journal.pone.0105376 [PubMed 25140533]
  147. Jaguga F. Clozapine-induced stuttering in the absence of known risk factors: a case report. J Med Case Rep. 2021;15(1):174. doi:10.1186/s13256-021-02803-8 [PubMed 33863375]
  148. Jones ME, Campbell G, Patel D, et al. Risk of mortality (including sudden cardiac death) and major cardiovascular events in users of olanzapine and other antipsychotics: a study with the general practice research database. Cardiovasc Psychiatry Neurol. 2013;2013:647476. doi:10.1155/2013/647476 [PubMed 24416588]
  149. Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012;169(1):71-79. doi:10.1176/appi.ajp.2011.11030347 [PubMed 22193526]
  150. Kane JP, O'Neill FA. Clozapine-induced liver injury and pleural effusion. Ment Illn. 2014;6(2):5403. doi:10.4081/mi.2014.5403 [PubMed 25553232]
  151. Kane J, Rubio JM, Kishimoto T, Correll CU. Treatment-resistant schizophrenia. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 18, 2024.
  152. Kang UG, Kwon JS, Ahn YM, et al. Electrocardiographic abnormalities in patients treated with clozapine. J Clin Psychiatry. 2000;61(6):441-446. doi:10.4088/jcp.v61n0609 [PubMed 10901343]
  153. Kanniah G, Kumar S. Clozapine associated cardiotoxicity: Issues, challenges and way forward. Asian J Psychiatr. 2020;50:101950. doi:10.1016/j.ajp.2020.101950 [PubMed 32109805]
  154. Kant R, Chalansani R, Chengappa KN, et al, "The Off-Label Use of Clozapine in Adolescents With Bipolar Disorder, Intermittent Explosive Disorder, or Posttraumatic Stress Disorder," J Child Adolesc Psychopharmacol, 2004, 14(1):57-63. [PubMed 15142392]
  155. Kaplan AM, Pitts WB, Ahmed I. An unexpected circumstance: acute dystonic reaction in the setting of clozapine administration. J Pharm Pract. 2019;32(1):103-105. doi:10.1177/0897190017737696 [PubMed 29092658]
  156. Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901 [PubMed 32867516]
  157. Kerwin RW, Osborne S, Sainz-Fuertes R. Heat stroke in schizophrenia during clozapine treatment: rapid recognition and management. J Psychopharmacol. 2004;18(1):121-123. [PubMed 15107195]
  158. Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet. 1999;354(9193):1841-1845. doi:10.1016/s0140-6736(99)10385-4 [PubMed 10584719]
  159. Kirpekar CV, Faye DA, Gawande S, Tadke R, Bhave SH. Clozapine induced supra ventricular tachycardia. Indian J Psychol Med. 2015;37(2):254-255. doi:10.4103/0253-7176.155685 [PubMed 25969624]
  160. Kitagawa K, Uekusa S, Matsuo K, et al. Risk factors for clozapine-induced central nervous system abnormalities in Japanese patients with treatment-resistant schizophrenia. Asian J Psychiatr. 2021;60:102652. doi:10.1016/j.ajp.2021.102652 [PubMed 33866283]
  161. Kluge M, Himmerich H, Wehmeier PM, et al. Sleep propensity at daytime as assessed by Multiple Sleep Latency Tests (MSLT) in patients with schizophrenia increases with clozapine and olanzapine. Schizophr Res. 2012;135(1-3):123-127. doi:10.1016/j.schres.2011.12.017 [PubMed 22257975]
  162. Kluge M, Schuld A, Schacht A, et al. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology. 2009;34(1):118-128. doi:10.1016/j.psyneuen.2008.08.016 [PubMed 18835660]
  163. Knoph KN, Morgan RJ 3rd, Palmer BA, et al. Clozapine-induced cardiomyopathy and myocarditis monitoring: a systematic review. Schizophr Res. 2018;199:17-30. doi:10.1016/j.schres.2018.03.006 [PubMed 29548760]
  164. Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome--a case review. Hum Psychopharmacol. 2003;18(4):301-309. doi:10.1002/hup.483 [PubMed 12766935]
  165. Kohen I, Afzal N, Hussain S, Manu P. Increases in C-reactive protein may predict recurrence of clozapine-induced fever. Ann Pharmacother. 2009;43(1):143-146. doi:10.1345/aph.1L467 [PubMed 19126823]
  166. Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med. 2001;111(9):716-723. doi:10.1016/s0002-9343(01)01000-2 [PubMed 11747852]
  167. Komaryk A, Elbe D, Burgess L. Retrospective review of clozapine use in children and adolescents. J Can Acad Child Adolesc Psychiatry. 2021;30(1):36-48. [PubMed 33552171]
  168. Koren W, Koren E, Nacasch N, Ehrenfeld M, Gur H. Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes. Clin Neuropharmacol. 1998;21(4):262-264. [PubMed 9704170]
  169. Kranzler HN, Kester HM, Gerbino-Rosen G, et al, "Treatment-Refractory Schizophrenia in Children and Adolescents: An Update on Clozapine and Other Pharmacologic Interventions," Child Adolesc Psychiatr Clin N Am, 2006, 15(1):135-59. [PubMed 16321728]
  170. Kranzler H, Roofeh D, Gerbino-Rosen G, et al, "Clozapine: Its Impact on Aggressive Behavior Among Children and Adolescents With Schizophrenia," J Am Acad Child Adolesc Psychiatry, 2005, 44(1):55-63. [PubMed 15608544]
  171. Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS. Atypical antipsychotics for psychosis in adolescents. Cochrane Database Syst Rev. 2013;(10):CD009582. [PubMed 24129841]
  172. Kumar P, Mishra DK, Mishra N, Ahuja S, Raghuvanshi G, Niranjan V. Acute onset clozapine-induced hyperglycaemia: a case report. Gen Psychiatr. 2019;32(2):e100045. doi:10.1136/gpsych-2018-100045 [PubMed 31179433]
  173. Kumar R, Sharma A, Kaur N, Singh A, Chhabra M, Sharma R. A case report on clozapine-induced ventricular ectopics: a fatal adverse drug reaction. J Basic Clin Physiol Pharmacol. 2020;31(3):/j/jbcpp.2020.31.issue-3/jbcpp-2019-0339/jbcpp-2019-0339.xml. doi:10.1515/jbcpp-2019-0339 [PubMed 32304306]
  174. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry. 1996;53(12):1090-1097. [PubMed 8956674]
  175. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry. 2008;63(5):524-529. [PubMed 17651705]
  176. Kwok JS, Chan TY. Recurrent heat-related illnesses during antipsychotic treatment. Ann Pharmacother. 2005;39(11):1940-1942. doi:10.1345/aph.1G130 [PubMed 16174785]
  177. Lally J, OʼConnor N, Fullam S, et al. Rechallenge following clozapine-associated eosinophilia: a case report and literature review. J Clin Psychopharmacol. 2019;39(5):504-506. doi:10.1097/JCP.0000000000001079 [PubMed 31335444]
  178. Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. J Clin Psychiatry. 2007;68(suppl 6):10-13. [PubMed 17650054]
  179. Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbæk G. Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. Am J Geriatr Psychiatry. 2014;22(4):321-331. doi:10.1016/j.jagp.2013.06.007 [PubMed 24016844]
  180. Layton D, Harris S, Wilton LV, Shakir SA. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. J Psychopharmacol. 2005;19(5):473-482. doi:10.1177/0269881105056524 [PubMed 16166184]
  181. Lee HB, Hanner JA, Yokley JL, Appleby B, Hurowitz L, Lyketsos CG. Clozapine for treatment-resistant agitation in dementia. J Geriatr Psychiatry Neurol. 2007;20(3):178-182. doi:10.1177/0891988707303335 [PubMed 17712102]
  182. Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry. 1994;55 Suppl B:82-87. [PubMed 7961582]
  183. Legge SE, Walters JT. Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective. Pharmacogenomics. 2019;20(4):279-290. doi:10.2217/pgs-2018-0188 [PubMed 30767710]
  184. Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association, Steering Committee on Practice Guidelines. Practice guidelines for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 suppl):1-56. [PubMed 15000267]
  185. Lertxundi U, Hernandez R, Medrano J, Domingo-Echaburu S, García M, Aguirre C. Antipsychotics and seizures: higher risk with atypicals? Seizure. 2013;22(2):141-143. doi:10.1016/j.seizure.2012.10.009 [PubMed 23146619]
  186. Leung JG, Nelson S, Takala CR, et al. Infection and inflammation leading to clozapine toxicity and intensive care: a case series. Ann Pharmacother. 2014;48(6):801-805. doi: 10.1177/1060028014526701. [PubMed 24619948]
  187. Levine SZ, Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophr Bull. 2010;36(3):624-632. doi:10.1093/schbul/sbn120 [PubMed 18849294]
  188. Li CR, Chung YC, Park TW, et al. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug. World J Biol Psychiatry. 2009;10(4 Pt 3):919-924. doi:10.1080/15622970802481895 [PubMed 19995222]
  189. Li JK, Yeung VT, Leung CM, et al. Clozapine: a mimicry of phaeochromocytoma. Aust N Z J Psychiatry. 1997;31(6):889-891. doi:10.3109/00048679709065519 [PubMed 9483266]
  190. Li X-B, Tang Y-L, Wang C-Y, et al. Clozapine for treatment-resistant bipolar disorder: A systematic review. Bipolar Disorders. 2015;17:235-247. doi: 10.1111/bdi.12272 [PubMed 25346322]
  191. Liu CL, Maruf AA, Bousman CA. Reporting of clozapine-induced gastrointestinal hypomotility and factors associated with fatal outcomes in Canada: a pharmacovigilance database study. Psychiatry Res. 2020;290:113048. doi:10.1016/j.psychres.2020.113048 [PubMed 32474068]
  192. Liu X, Kolding L, Momen N, Gasse C, Pedersen LH. Maternal antipsychotic use during pregnancy and congenital malformations. Am J Obstet Gynecol MFM. 2023;5(6):100950. doi:10.1016/j.ajogmf.2023.100950 [PubMed 37015311]
  193. Low RA Jr, Fuller MA, Popli A. Clozapine induced atrial fibrillation. J Clin Psychopharmacol. 1998;18(2):170. doi:10.1097/00004714-199804000-00010 [PubMed 9555602]
  194. Lowe EJ and Ackman ML. Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment. Ann Pharmacother. 2010; 44(4):727-732. [PubMed 20233914]
  195. Ma SM, Lim J, Jiang C, Luca L. Esophagitis after clozapine use in a 61-year-old woman with refractory schizophrenia. Case Rep Psychiatry. 2022;2022:7033038. doi:10.1155/2022/7033038 [PubMed 35693728]
  196. Mace S, Dzahini O, Cornelius V, Langerman H, Oloyede E, Taylor D. Incident infection during the first year of treatment - a comparison of clozapine and paliperidone palmitate long-acting injection. J Psychopharmacol. 2022;36(2):232-237. doi:10.1177/02698811211058973 [PubMed 34991402]
  197. Maddalena AS, Fox M, Hofmann M, et al. Esophageal dysfunction on psychotropic medication. A case report and literature review. Pharmacopsychiatry. 2004;37(3):134-138. [PubMed 15138897]
  198. Mady SP and Wax P, "Clozapine Intoxication in a Young Child," Vet Hum Toxicol, 1993, 35(4):338.
  199. Maher KN, Tan M, Tossell JW, et al. Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia. J Child Adolesc Psychopharmacol. 2013;23(2):110‐116. [PubMed 23510445]
  200. Maixner SM, Mellow AM, Tandon R. The efficacy, safety, and tolerability of antipsychotics in the elderly. J Clin Psychiatry. 1999;60(suppl 8):29-41. [PubMed 10335669]
  201. Majumder P, Chadda RK, Goyal P, Mittal A, Kumar N. Clozapine induced eosinophilia. Indian J Psychiatry. 2011;53(2):152-153. doi:10.4103/0019-5545.82546 [PubMed 21772649]
  202. Manu P, Lapitskaya Y, Shaikh A, Nielsen J. Clozapine rechallenge after major adverse effects: clinical guidelines based on 259 cases. Am J Ther. 2018;25(2):e218-e223. doi:10.1097/MJT.0000000000000715 [PubMed 29505490]
  203. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161(8):1334-1349. [PubMed 15285957]
  204. Marder S. Psychosis in adults: initial management. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 11, 2024.
  205. Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR. The side-effects of clozapine: a four year follow-up study. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18(3):537-544. doi:10.1016/0278-5846(94)90010-8 [PubMed 8078987]
  206. Martinez M, Devenport L, Saussy J, Martinez J. Drug-associated heat stroke. South Med J. 2002;95(8):799-802. [PubMed 12190212]
  207. Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015;72(5):438-445. doi:10.1001/jamapsychiatry.2014.3018 [PubMed 25786075]
  208. McAllister-Williams RH, Baldwin DS, Cantwell R, et al. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J Psychopharmacol. 2017;31(5):519-552. doi:10.1177/0269881117699361 [PubMed 28440103]
  209. McCarthy RH, Terkelsen KG. Esophageal dysfunction in two patients after clozapine treatment. J Clin Psychopharmacol. 1994;14(4):281-283. [PubMed 7962688]
  210. McClellan J, Kowatch R, Findling RL, Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(1):107-125. [PubMed 17195735]
  211. McCloskey LR, Wisner KL, Cattan MK, Betcher HK, Stika CS, Kiley JW. Contraception for women with psychiatric disorders. Am J Psychiatry. 2021;178(3):247-255. doi:10.1176/appi.ajp.2020.20020154 [PubMed 33167674]
  212. McCollum B, Barclay J, de Leon J. Unexpected falls during clozapine treatment explained by myoclonus. Prim Care Companion CNS Disord. 2018;20(1):17l02151. doi:10.4088/PCC.17l02151 [PubMed 29360288]
  213. Mehta TM, Van Lieshout RJ. A review of the safety of clozapine during pregnancy and lactation. Arch Womens Ment Health. 2017;20(1):1-9. doi:10.1007/s00737-016-0670-0 [PubMed 27704220]
  214. Mendhekar DN. Possible delayed speech acquisition with clozapine therapy during pregnancy and lactation. J Neuropsychiatry Clin Neurosci. 2007;19:196-197. doi:10.1176/jnp.2007.19.2.196 [PubMed 17431071]
  215. Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol. 2005;25(1):32-41. doi:10.1097/01.jcp.0000150217.51433.9f [PubMed 15643098]
  216. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: Evaluation and treatment of depression, psychosis and dementia in Parkinson disease (an evidence-based review); Report of the Quality Standards subcommittee of the American Academy of Neurology. Am Acad Neurol. 2006; 66:996-1002. doi: 10.1212/01.wnl.0000215428.46057.3d [PubMed 16606910]
  217. Mijovic A, MacCabe JH. Clozapine-induced agranulocytosis. Ann Hematol. 2020;99(11):2477-2482. doi:10.1007/s00277-020-04215-y [PubMed 32815018]
  218. Moazez C, Rudha Y, Narang N, Younger T. A rare presentation of clozapine-induced DRESS syndrome. Case Rep Med. 2018;2018:1346351. [PubMed 29991947]
  219. Modai I, Hirschmann S, Rava A, et al. Sudden death in patients receiving clozapine treatment: a preliminary investigation. J Clin Psychopharmacol. 2000;20(3):325-327. doi:10.1097/00004714-200006000-00006 [PubMed 10831019]
  220. Moncrieff J, Gupta S, Horowitz MA. Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder. Ther Adv Psychopharmacol. Published online July 6, 2020. doi:10.1177/2045125320937910 [PubMed 32670542]
  221. Monteleone F, Gonçalves M, Fonseca L, et al. Clozapine-induced eosinophilia: a case report. Rev Colomb Psiquiatr (Engl Ed). Published online June 21, 2021. doi:10.1016/j.rcp.2021.04.004 [PubMed 34167790]
  222. Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004;27(4):153-156. doi:10.1097/01.wnf.0000136891.17006.ec [PubMed 15319699]
  223. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry. 1993;50(9):723-733. doi:10.1001/archpsyc.1993.01820210057007 [PubMed 8102845]
  224. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010;81(5):617-622. [PubMed 20187598]
  225. Myles H, Large M. Considering the impact of viral illness on the aetiology of clozapine myocarditis. Aust N Z J Psychiatry. 2021;55(2):226. doi:10.1177/0004867420945793 [PubMed 32698608]
  226. Myles N, Myles H, Xia S, et al. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand. 2018;138(2):101-109. doi: 10.1111/acps.12898. [PubMed 29786829]
  227. Nakajima N, Misawa F, Fujii Y, Takeuchi H. Clozapine-related gastrointestinal perforation: four case reports. Aust N Z J Psychiatry. 2020;54(5):541-542. doi:10.1177/0004867419887231 [PubMed 31718230]
  228. Nanasawa H, Sako A, Mitsutsuka T, et al. Development of diabetes mellitus associated with quetiapine: a case series. Medicine (Baltimore). 2017;96(3):e5900. doi:10.1097/MD.0000000000005900 [PubMed 28099349]
  229. National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health. Psychosis and schizophrenia in children and young people: recognition and management. 2013. https://www.nice.org.uk/guidance/cg155 [PubMed 26065063]
  230. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19 Suppl 1:1-93. doi:10.2165/00023210-200519001-00001 [PubMed 15998156]
  231. Nielsen J, Correll CU, Manu P, Kane JM. Termination of clozapine treatment due to medical reasons: When is it warranted and how can it be avoided? J Clin Psych. 2013;74(6): 603-613.
  232. Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome-an 11-year longitudinal case-control study. Can J Psychiatry. 2012;57(8):512-518. doi:10.1177/070674371205700810 [PubMed 22854034]
  233. O'Neill JL, Remington TL. Drug-induced esophageal injuries and dysphagia. Ann Pharmacother. 2003;37(11):1675-1684. doi:10.1345/aph.1D056 [PubMed 14565800]
  234. Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry. 2006;163(10):1821-1825. doi:10.1176/ajp.2006.163.10.1821 [PubMed 17012695]
  235. Osterman MT, Foley C, Matthias I. Clozapine-induced acute gastrointestinal necrosis: a case report. J Med Case Rep. 2017;11(1):270. doi:10.1186/s13256-017-1447-4 [PubMed 28938913]
  236. Ozdemir V, Kalow W, Okey AB, et al. Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol. 2001;21(6):603-607. [PubMed 11763009]
  237. Paciullo CA. Evaluating the association between clozapine and venous thromboembolism. Am J Health Syst Pharm.2008;65(19):1825-9. [PubMed 18796423]
  238. Papazisis G, Tzellos T, Tahmatzidis D, Dolianitis K, Kouvelas D. Late-onset clozapine-induced hypothermia accompanied by electrocardiogram Osborn waves. J Clin Psychopharmacol. 2009;29(2):183-185. doi:10.1097/JCP.0b013e31819a6a0d [PubMed 19512984]
  239. Palmer SE, McLean RM, Ellis PM, et al. Life-Threatening Clozapine-Induced Gastrointestinal Hypomotility: An Analysis of 102 Cases. J Clin Psychiatry. 2008;69(5):759-68. [PubMed 18452342]
  240. Pardis P, Remington G, Panda R, Lemez M, Agid O. Clozapine and tardive dyskinesia in patients with schizophrenia: a systematic review. J Psychopharmacol. 2019;33(10):1187-1198. doi:10.1177/0269881119862535 [PubMed 31347436]
  241. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. NEJM. 1999;340:757-763. doi: 10.1056/NEJM199903113401003 [PubMed 10072410]
  242. Patel RK, Moore AM, Piper S, et al. Clozapine and cardiotoxicity - a guide for psychiatrists written by cardiologists. Psychiatry Res. 2019;282:112491. doi:10.1016/j.psychres.2019.112491 [PubMed 31351758]
  243. Patterson-Lomba O, Ayyagari R, Carroll B. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis. BMC Neurol. 2019;19(1):174. doi:10.1186/s12883-019-1385-4 [PubMed 31325958]
  244. Pearlman C. Clozapine, nocturnal sialorrhea, and choking. J Clin Psychopharmacol. 1994;14(4):283. doi:10.1097/00004714-199408000-00013 [PubMed 7962689]
  245. Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv. 1998;49(9):1163-1172. doi:10.1176/ps.49.9.1163 [PubMed 9735957]
  246. Penaskovic KM, Annamraju S, Kraus JE. Clozapine-induced allergic vasculitis. Am J Psychiatry. 2005;162(8):1543. doi:10.1176/appi.ajp.162.8.1543 [PubMed 16055784]
  247. Pierides M. Clozapine monotherapy and ketoacidosis. Br J Psychiatry. 1997;171:90-91. doi:10.1192/bjp.171.1.90c [PubMed 9328511]
  248. Pintor L, Valldeoriola F, Baillés E, Martí MJ, Muñiz A, Tolosa E. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Clin Neuropharmacol. 2012;35(2):61-66. doi:10.1097/WNF.0b013e31824d5115 [PubMed 22388466]
  249. Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R. Effects of psychotropic drugs on seizure threshold. Drug Saf. 2002;25(2):91-110. doi:10.2165/00002018-200225020-00004 [PubMed 11888352]
  250. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75(5):689-695. doi:10.1136/jnnp.2003.029868 [PubMed 15090561]
  251. Post RM. Bipolar disorder in adults: Choosing maintenance treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 29. 2020.
  252. Poudyal R, Lohani S. Clozapine associated pulmonary embolism: systematic review. J Community Hosp Intern Med Perspect. 2019;9(4):300-304. doi:10.1080/20009666.2019.1627848 [PubMed 31528276]
  253. Praharaj SK, Arora M, Gandotra S. Clozapine-induced sialorrhea: pathophysiology and management strategies. Psychopharmacology (Berl). 2006;185(3):265-273. [PubMed 16514524]
  254. Praharaj SK, Jana AK, Goswami K, Das PR, Goyal N, Sinha VK. Salivary flow rate in patients with schizophrenia on clozapine. Clin Neuropharmacol. 2010;33(4):176-178. doi:10.1097/WNF.0b013e3181e204e0 [PubMed 20661023]
  255. Praharaj SK, Venkatesh BG, Sarkhel S, Zia-ul-Haq M, Sinha VK. Clozapine-induced myoclonus: a case study and brief review. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(1):242-243. doi:10.1016/j.pnpbp.2009.10.006 [PubMed 19833162]
  256. Pridan S, Swartz M, Baruch Y, Tadger S, Plopski I, Barak Y. Effectiveness and safety of clozapine in elderly patients with chronic resistant schizophrenia. International Psychogeriatrics. 2015;27(1):131-134. [PubMed 25166892]
  257. Rajagopal S. Clozapine, agranulocytosis, and benign ethnic neutropenia. Postgrad Med J. 2005;81(959):545-546. doi:10.1136/pgmj.2004.031161 [PubMed 16143678]
  258. Rajji TK, Uchida H, Ismail Z, et al. Clozapine and global cognition in schizophrenia. J Clin Psychopharmacol. 2010;30(4):431-436. doi:10.1097/JCP.0b013e3181e69060 [PubMed 20631560]
  259. Ramos Perdigués S, Sauras Quecuti R, Mané A, Mann L, Mundell C, Fernandez-Egea E. An observational study of clozapine induced sedation and its pharmacological management. Eur Neuropsychopharmacol. 2016;26(1):156-161. doi:10.1016/j.euroneuro.2015.11.006 [PubMed 26613638]
  260. Rask SM, Luoto KE, Solismaa A, Jokinen E, Jussila A, Kampman O. Clozapine-related diarrhea and colitis: report of 4 cases. J Clin Psychopharmacol. 2020;40(3):293-296. doi:10.1097/JCP.0000000000001204 [PubMed 32332465]
  261. Refer to manufacturer's labeling.
  262. Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry. 2017;62(9):604-616. doi:10.1177/0706743717720448 [PubMed 28703015]
  263. Remington G, Agid O, Foussias G, Ferguson L, McDonald K, Powell V. Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology (Berl). 2013;225(3):505-518. [PubMed 23179967]
  264. Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? Schizophr Res. 2005;76(2-3):267-272. doi: 10.1016/j.schres.2005.01.009. [PubMed 15949658]
  265. Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543-546. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2015.173501. Accessed May 26, 2016. doi:10.1176/appi.ajp.2015.173501 [PubMed 27133416]
  266. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426 [PubMed 14999113]
  267. Rojo LE, Gaspar PA, Silva H, et al. Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. Pharmacol Res. 2015;101:74-85. doi:10.1016/j.phrs.2015.07.022 [PubMed 26218604]
  268. Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, Wolfe R, McNeil JJ. Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study. Schizophr Res. 2012;141(2-3):173-178. doi:10.1016/j.schres.2012.08.018 [PubMed 23010488]
  269. Ronaldson KJ, Taylor AJ, Fitzgerald PB, Topliss DJ, Elsik M, McNeil JJ. Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls. J Clin Psychiatry. 2010;71(8):976-981. doi:10.4088/JCP.09m05024yel [PubMed 20361910]
  270. Sachdev P, Kruk J, Kneebone M, Kissane D. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol. 1995;15(5):365-371. doi:10.1097/00004714-199510000-00010 [PubMed 8830069]
  271. Saenger RC, Finch TH, Francois D. Aspiration pneumonia due to clozapine-induced sialorrhea. Clin Schizophr Relat Psychoses. 2016;9(4):170-172. doi:10.3371/CSRP.SAFI.061213 [PubMed 23773887]
  272. Sahyouni C, Hefazi E. Clozapine induced pericarditis: a case report. Psychiatry Res. 2021;305:114250. doi:10.1016/j.psychres.2021.114250 [PubMed 34749222]
  273. Sanader B, Grohmann R, Grötsch P, et al. Clozapine-induced DRESS syndrome: a case series from the AMSP multicenter drug safety surveillance project. Pharmacopsychiatry. 2019;52(3):156-159. doi:10.1055/a-0586-8983 [PubMed 29554696]
  274. Sarvaiya N, Lapitskaya Y, Dima L, Manu P. Clozapine-associated pulmonary embolism: a high-mortality, dose-independent and early-onset adverse effect. Am J Ther. 2018;25(4):e434-e438. doi:10.1097/MJT.0000000000000806 [PubMed 29985823]
  275. Schaber G, Stevens I, Gaertner HJ, Dietz K, Breyer-Pfaff U. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. Br J Clin Pharmacol. 1998;46(5):453-459. doi:10.1046/j.1365-2125.1998.00822.x [PubMed 9833598]
  276. Schneider C, Corrigall R, Hayes D, Kyriakopoulos M, Frangou S. Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia. Eur Psychiatry. 2014;29(1):1-10. [PubMed 24119631]
  277. Seitz DP, Gill SS. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature. Psychosomatics. 2009;50(1):8-15. doi:10.1176/appi.psy.50.1.8 [PubMed 19213967]
  278. Senn HJ, Jungi WF, Kunz H, Pöldinger W. Clozapine and agranulocytosis. Lancet. 1977;1(8010):547. doi:10.1016/s0140-6736(77)91410-6 [PubMed 65644]
  279. Sharma TR, Chahil R. Dose dependent, new onset QTc prolongation in a patient with paranoid schizophrenia receiving Clozapine. Asian J Psychiatr. 2011;4(3):221-222. doi:10.1016/j.ajp.2011.06.005 [PubMed 23051123]
  280. Shaw P, Sporn A, Gogtay N, et al, "Childhood-Onset Schizophrenia: A Double-Blind, Randomized, Clozapine-Olanzapine Comparison," Arch Gen Psych, 2006, 63(7):721-30. [PubMed 16818861]
  281. Sheehan JJ, Sliwa JK, Amatniek JC, Grinspan A, Canuso CM. Atypical antipsychotic metabolism and excretion. Curr Drug Metab. 2010;11(6):516-525. [PubMed 20540690]
  282. Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol. 2012;8(1):15-21. doi:10.3988/jcn.2012.8.1.15 [PubMed 22523509]
  283. Shirani A, Paradiso S, Dyken ME. The impact of atypical antipsychotic use on obstructive sleep apnea: a pilot study and literature review. Sleep Med. 2011;12(6):591-597. [PubMed 21645873]
  284. Shuman MD, Trigoboff E, Demler TL, Opler LA. Exploring the potential effect of polypharmacy on the hematologic profiles of clozapine patients. J Psychiatr Pract. 2014;20(1):50-58. doi:10.1097/01.pra.0000442937.61575.26 [PubMed 24419309]
  285. Siskind D, Honer WG, Clark S, et al. Consensus statement on the use of clozapine during the COVID-19 pandemic [published online April 3, 2020]. J Psychiatry Neurosci. 2020a;45(4):200061. doi:10.1503/jpn.200061 [PubMed 32242646]
  286. Siskind D, Sidhu A, Cross J, et al. Systematic review and meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy. Aust N Z J Psychiatry. 2020b;54(5):467-481. doi:10.1177/0004867419898760 [PubMed 31957459]
  287. Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol. 2007;27(2):159-169. [PubMed 17390261]
  288. Solmi M, Murru A, Pacchiarotti, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757-777. doi: 10.2147/TCRM.S117321. [PubMed 28721057]
  289. Solmi M, Pigato G, Kane JM, Correll CU. Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci. 2018;389:21-27. doi:10.1016/j.jns.2018.02.012 [PubMed 29439776]
  290. Sporn AL, Vermani A, Greenstein DK, et al. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry. 2007;46(10):1349-1356. doi:10.1097/chi.0b013e31812eed10 [PubMed 17885577]
  291. Squires RF, Saederup E. Clozapine and several other antipsychotic/antidepressant drugs preferentially block the same 'core' fraction of GABA(A) receptors. Neurochem Res. 1998;23(10):1283-1290. doi:10.1023/a:1020796200769 [PubMed 9804284]
  292. Srinivasaraju R, Reddy YC, Pal PK, Math SB. Clozapine-associated cerebral venous thrombosis. J Clin Psychopharmacol. 2010;30(3):335-336. doi:10.1097/JCP.0b013e3181deb88a [PubMed 20473075]
  293. Steinert T, Jans F. Six cases of perforated appendicitis during clozapine treatment. J Clin Psychiatry. 2021;82(4):20cr13841. doi:10.4088/JCP.20cr13841 [PubMed 34166590]
  294. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother. 2008;42(9):1290-1297. doi:10.1345/aph.1L066 [PubMed 18628446]
  295. Stigler KA, Potenza MN, McDougle CJ. Tolerability profile of atypical antipsychotics in children and adolescents. Paediatr Drugs. 2001;3(12):927-942. doi:10.2165/00128072-200103120-00005 [PubMed 11772153]
  296. Stöllberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005;20(5):243-251. doi:10.1097/01.yic.0000166405.49473.70 [PubMed 16096514]
  297. Straub L, Hernández-Díaz S, Bateman BT, et al. Association of antipsychotic drug exposure in pregnancy with risk of neurodevelopmental disorders: a national birth cohort study. JAMA Intern Med. 2022;182(5):522-533. doi:10.1001/jamainternmed.2022.0375 [PubMed 35343998]
  298. Stovall J. Bipolar mania and hypomania in adults: choosing pharmacotherapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 3, 2021.
  299. Suvarna P, Kayarkatte MN, Shenoi SD, Jaiprakash P. A rare case of clozapine-induced symmetrical drug-related intertriginous and flexural exanthema with vasculitis-like lesions. Contact Dermatitis. 2020;82(5):318-320. doi:10.1111/cod.13468 [PubMed 31922262]
  300. Swetlik C, Cohen LS, Kobylski LA, et al. Effects of prenatal exposure to second-generation antipsychotics on development and behavior among preschool-aged children: preliminary results from the National Pregnancy Registry for Psychiatric Medications. J Clin Psychiatry. 2024;85(1):23m14965. doi:10.4088/JCP.23m14965 [PubMed 38488388]
  301. Szota A, Ogłodek E, Araszkiewicz A. Fever development in neuroleptic malignant syndrome during treatment with olanzapine and clozapine. Pharmacol Rep. 2013;65(2):279-287. doi:10.1016/s1734-1140(13)71004-1 [PubMed 23744413]
  302. Szota AM, Araszkiewicz AS. The risk factors, frequency and diagnosis of atypical antipsychotic drug-induced hypothermia: practical advice for doctors. Int Clin Psychopharmacol. 2019;34(1):1-8. doi:10.1097/YIC.0000000000000244 [PubMed 30398998]
  303. Taipale H, Tanskanen A, Mehtälä J, Vattulainen P, Correll CU, Tiihonen J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19(1):61-68. doi:10.1002/wps.20699 [PubMed 31922669]
  304. Takeuchi H, Kantor N, Uchida H, Suzuki T, Remington G. Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis. Schizophr Bull. 2017;43(4):862-871. doi:10.1093/schbul/sbw171 [PubMed 28044008]
  305. Takeuchi H, Powell V, Geisler S, et al. Clozapine administration in clinical practice: once-daily versus divided dosing. Acta Psychiatr Scand. 2016;134(3):234-240. doi:10.1111/acps.12593 [PubMed 27182769]
  306. Tan MSA, Honarparvar F, Falconer JR, Parekh HS, Pandey P, Siskind DJ. A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions. Psychopharmacology (Berl). 2021;238(3):615-637. doi:10.1007/s00213-020-05746-y [PubMed 33410989]
  307. Tanner MA, Culling W. Clozapine associated dilated cardiomyopathy. Postgrad Med J. 2003;79(933):412-413. doi:10.1136/pmj.79.933.412 [PubMed 12897222]
  308. Tatar ZB, Oflaz S, Baran B. A case of late-onset angioedema associated with clozapine and redevelopment of angioedema with olanzapine. J Clin Psychopharmacol. 2014;34(4):523-525. doi:10.1097/JCP.0000000000000153 [PubMed 24911442]
  309. Taylor MA, Fink M. Catatonia in psychiatric classification: a home of its own. Am J Psychiatry. 2003;160(7):1233-1241. doi:10.1176/appi.ajp.160.7.1233 [PubMed 12832234]
  310. Teodorescu A, Dima L, Ifteni P, Rogozea LM. Clozapine for treatment-refractory behavioral disturbance in dementia. Am J Ther. 2018;25(3):e320-e325. doi:10.1097/MJT.0000000000000735 [PubMed 29401113]
  311. Teodoro T, Nogueira V, Aldeias J, Teles Martins M, Salgado J. Clozapine associated periorbital edema in first episode psychosis: a case report of a rare adverse effect in treatment-resistant schizophrenia. J Clin Psychopharmacol. 2022;42(6):594-596. doi:10.1097/JCP.0000000000001600 [PubMed 36066404]
  312. Terrana N, Koren G, Pivovarov J, Etwel F, Nulman I. Pregnancy outcomes following in utero exposure to second-generation antipsychotics: a systematic review and meta-analysis. J Clin Psychopharmacol. 2015;35(5):559-565. doi:10.1097/JCP.0000000000000391 [PubMed 26274044]
  313. Thanigaivel R, Bretag-Norris R, Amos A, McDermott B. A systematic review of maternal and infant outcomes after clozapine continuation in pregnancy. Int J Psychiatry Clin Pract. 2022;26(2):178-182. doi:10.1080/13651501.2021.1936070 [PubMed 34110979]
  314. Thomson SR, Patil N, Ommurugan B, Bhandary RK. A case of hyper sexuality probably associated with clozapine. Psychopharmacol Bull. 2018;48(4):20-24. [PubMed 30618473]
  315. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620-627. doi:10.1016/S0140-6736(09)60742-X [PubMed 19595447]
  316. Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. Circulation. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905 [PubMed 32929996]
  317. Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients [published correction appears in Circ Cardiovasc Qual Outcomes. 2013;6(6):e57]. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152 [PubMed 23716032]
  318. Tisdale JE, Jaynes HA, Kingery JR, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients [published correction appears in Circ Cardiovasc Qual Outcomes. 2014;7(6):981]. Circ Cardiovasc Qual Outcomes. 2014;7(3):381-390. doi:10.1161/CIRCOUTCOMES.113.000651 [PubMed 24803473]
  319. Tohen M, Jacobs TG, Feldman PD. Onset of action of antipsychotics in the treatment of mania. Bipolar Disord. 2000;2(3 pt 2):261-268. doi:10.1034/j.1399-5618.2000.20307.x [PubMed 11249804]
  320. Torrico T, Crandall RO, Meza C, Abdijadid S. Clozapine-induced pneumonitis: a case report. Front Psychiatry. 2020;11:572102. doi:10.3389/fpsyt.2020.572102 [PubMed 33173520]
  321. Tripp AC. Nonfatal pulmonary embolus associated with clozapine treatment: a case series. Gen Hosp Psychiatry. 2011;33(1). doi:10.1016/j.genhosppsych.2010.11.010 [PubMed 21353146]
  322. Trollor JN, Chen X, Chitty K, Sachdev PS. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. Br J Psychiatry. 2012;201(1):52-56. doi:10.1192/bjp.bp.111.105189 [PubMed 22626633]
  323. Tsuda Y, Saruwatari J, Yasui-Furukori N. Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. BMJ Open. 2014;4(3):e004216. [PubMed 24595134]
  324. Turetz M, Mozes T, Toren P, et al. An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia. Br J Psychiatry. 1997;170:507-510. doi:10.1192/bjp.170.6.507 [PubMed 9330014]
  325. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000 [PubMed 20000886]
  326. Uguz F. The use of clozapine during pregnancy and lactation: a case report. Psychiat Clin Psychopharmacol. 2020;30:193-195. doi:10.5455/PCP.20200502080433
  327. Uygur OF, Uygur H. Neurodevelopmental and growth follow-up of the baby exposed to antipsychotics during pregnancy and lactation: a case report. Psychiat Clin Psychopharmacol. 2019;29:744-747. doi:10.1080/24750573.2019.1627695
  328. Uzun Ö, Bolu A, Taşçi AB, Oğur B. Knee buckling (negative myoclonus) associated with clozapine: reports on 3 cases. Clin Neuropharmacol. 2020;43(1):26-27. doi:10.1097/WNF.0000000000000370 [PubMed 31738190]
  329. Valladales-Restrepo LF, Duran-Lengua M, Machado-Alba JE. Potentially inappropriate prescriptions of anticholinergics drugs in Alzheimer's disease patients. Geriatr Gerontol Int. 2019;19(9):913-917. doi:10.1111/ggi.13748 [PubMed 31342625]
  330. van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. BMJ. 1999;319(7210):623-626. doi:10.1136/bmj.319.7210.623 [PubMed 10473482]
  331. van Marum RJ, Wegewijs MA, Loonen AJ, Beers E. Hypothermia following antipsychotic drug use. Eur J Clin Pharmacol. 2007;63(6):627-631. doi:10.1007/s00228-007-0294-4 [PubMed 17401555]
  332. van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2008;69(3):472-479. doi:10.4088/jcp.v69n0320 [PubMed 18348593]
  333. VanderZwaag C, McGee M, McEvoy JP, Freudenreich O, Wilson WH, Cooper TB. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry. 1996;153(12):1579-1584. doi:10.1176/ajp.153.12.1579 [PubMed 8942454]
  334. Varma S, Bishara D, Besag FM, Taylor D. Clozapine-related EEG changes and seizures: dose and plasma-level relationships. Ther Adv Psychopharmacol. 2011;1(2):47-66. doi:10.1177/2045125311405566 [PubMed 23983927]
  335. Vasudev K, Choi YH, Norman R, Kim RB, Schwarz UI. Genetic determinants of clozapine-induced metabolic side effects. Can J Psychiatry. 2017;62(2):138-149. doi:10.1177/0706743716670128 [PubMed 27681143]
  336. Vayá A, Lopez M, Plumé G, Ribes J. Upper-extremity deep vein thrombosis in a patient on clozapine therapy carrying the prothrombin G20210A mutation. Pathophysiol Haemost Thromb. 2008;36(2):105-107. doi:10.1159/000173731 [PubMed 19127092]
  337. Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, Sutterland AL, Correll CU, de Haan L. Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years. Schizophr Bull. 2019;45(2):315-329. doi:10.1093/schbul/sby052 [PubMed 29697804]
  338. Versacloz (clozapine) [prescribing information]. Tampa, FL: TruPharma LLC; January 2025.
  339. Viguera AC, Freeman MP, Góez-Mogollón L, et al. Reproductive safety of second-generation antipsychotics: updated data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. J Clin Psychiatry. 2021;82(4):20m13745. doi:10.4088/JCP.20m13745 [PubMed 34352165]
  340. Viguera AC, McElheny SA, Caplin PS, et al. Risk of poor neonatal adaptation syndrome among infants exposed to second-generation atypical antipsychotics compared to antidepressants: results from the National Pregnancy Registry for Psychiatric Medications. J Clin Psychiatry. 2023;84(1):22m14492. doi:10.4088/JCP.22m14492 [PubMed 36602927]
  341. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013;3:tre-03-161-4138-1. doi:10.7916/D88P5Z71 [PubMed 23858394]
  342. Wang Y, Gong Y, Liu Z, Fu Z, Xue Y, Huang G. Acute bilateral coronary artery thrombosis and myocardial infarction in a 25-year-old man after long-term oral clozapine treatment. J Clin Psychopharmacol. 2020;40(1):84-86. doi:10.1097/JCP.0000000000001156 [PubMed 31834089]
  343. Wang Y, He R, Zhang H. Case report on clozapine-associated neuroleptic malignant syndrome. Shanghai Arch Psychiatry. 2012;24(2):116-117. doi:10.3969/j.issn.1002-0829.2012.02.009 [PubMed 25324614]
  344. Wang Z, Brauer R, Man KKC, Alfageh B, Mongkhon P, Wong ICK. Prenatal exposure to antipsychotic agents and the risk of congenital malformations in children: a systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(11):4101-4123. doi:10.1111/bcp.14839 [PubMed 33772841]
  345. Warner B, Hoffmann P. Investigation of the potential of clozapine to cause torsade de pointes. Adverse Drug React Toxicol Rev. 2002;21(4):189-203. doi:10.1007/BF03256196 [PubMed 12503253]
  346. Weiner DM, Meltzer HY, Veinbergs I, et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl). 2004;177(1-2):207-216. doi:10.1007/s00213-004-1940-5 [PubMed 15258717]
  347. Welten CC, Koeter MW, Wohlfarth TD, et al. Early nonresponse in the antipsychotic treatment of acute mania: a criterion for reconsidering treatment? Results from an individual patient data meta-analysis. J Clin Psychiatry. 2016;77(9):e1117-e1123. doi:10.4088/JCP.15r10051 [PubMed 27780320]
  348. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int. 2011;108(41):687-693. doi:10.3238/arztebl.2011.0687 [PubMed 22114630]
  349. Wheatley M, Plant J, Reader H, et al, "Clozapine Treatment of Adolescents With Posttraumatic Stress Disorder and Psychotic Symptoms," J Clin Psychopharmacol, 2004, 24(2):167-73. [PubMed 15206664]
  350. Wiciński M, Węclewicz MM. Clozapine-induced agranulocytosis/granulocytopenia: mechanisms and monitoring. Curr Opin Hematol. 2018;25(1):22-28. doi:10.1097/MOH.0000000000000391 [PubMed 28984748]
  351. Williams AM, Park SH. Seizure associated with clozapine: incidence, etiology, and management. CNS Drugs. 2015;29(2):101-111. doi:10.1007/s40263-014-0222-y [PubMed 25537107]
  352. Wong J, Delva N. Clozapine-induced seizures: recognition and treatment. Can J Psychiatry. 2007;52(7):457-463. doi:10.1177/070674370705200708 [PubMed 17688010]
  353. Wu CS, Wang SC, Yeh IJ, Liu SK. Comparative risk of seizure with use of first- and second-generation antipsychotics in patients with schizophrenia and mood disorders. J Clin Psychiatry. 2016;77(5):e573-e579. doi:10.4088/JCP.15m09898 [PubMed 27249081]
  354. Wu CY, Mitchell SR, Seyfried LS. Quetiapine-induced hyperglycemic crisis and severe hyperlipidemia: a case report and review of the literature. Psychosomatics. 2014;55(6):686-691. doi:10.1016/j.psym.2014.07.002 [PubMed 25497507]
  355. Wu MK, Chung W, Wu CK, Tseng PT. The severe complication of Stevens-Johnson syndrome induced by long-term clozapine treatment in a male schizophrenia patient: a case report. Neuropsychiatr Dis Treat. 2015;11:1039-1041. doi:10.2147/NDT.S79327 [PubMed 25914536]
  356. Wu Chou AI, Lu ML, Shen WW. Hepatotoxicity induced by clozapine: a case report and review of literature. Neuropsychiatr Dis Treat. 2014;10:1585-1587. doi:10.2147/NDT.S67654 [PubMed 25210451]
  357. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97-170. doi: 10.1111/bdi.12609. [PubMed 29536616]
  358. Yuen JWY, Kim DD, Procyshyn RM, White RF, Honer WG, Barr AM. Clozapine-induced cardiovascular side effects and autonomic dysfunction: a systematic review. Front Neurosci. 2018;12:203. doi:10.3389/fnins.2018.00203 [PubMed 29670504]
  359. Zonnenberg C, Bueno-de-Mesquita JM, Ramlal D, Blom JD. Hypothermia due to antipsychotic medication: a systematic review. Front Psychiatry. 2017;8:165. doi:10.3389/fpsyt.2017.00165 [PubMed 28936184]
Topic 9289 Version 685.0